Contenido - InfomedOct.- Dic. del 2002 Año 11 No. 4 COMITÉ EDITORIAL Presidenta Concepción Campa...

Oct.- Dic. del 2002 Año 11 No. 4

COMITÉ EDITORIAL

PresidentaConcepción Campa Huergo

VicepresidenteGustavo Sierra González

Editores EjecutivosOrlando Gutiérrez y Gilberto Sotolongo

AsesoresJuraj Ivanyi (UK) y Epifanio Selman (CU)

Editor Biología MolecularArmando Acosta

Editor InmunologíaArmando Cádiz

Editor MicrobiologíaIsabel Martínez

Editor EpidemiologíaJorge Menéndez

Editor TecnologíaArturo Talavera

Redactor JefeVirginia Betancourt

Corrección ReferenciasBertha Pimienta

TraducciónEloísa Le Riverend

Los artículos originales de estapublicación son arbitrados.

Se autoriza la reproducción de losmateriales originales publicados en esta

Revista, siempre que se indique suprocedencia.

El contenido de las informacionesaparecidas en esta Revista no expresa

necesariamente la opinión de laInstitución.

ISSN 1025-0298 (Versión Electrónica)

Calle 212 No. 3112 e/ 31 y 37, La Lisa.Ciudad de La Habana. Cuba.

Ap. 16017, Cod. 11600!!!! (53-7) 271 6557Fax: (53-7) 33 6754

E-mail: [email protected] Web: http://www.finlay.edu.cuhttp://www.sld.cu/instituciones/finlay/publicaciones/vaccimonitor/vm.htm

ontenidoontenidoontenidoontenido
CCCC
Los inmunológos latinoamericanos se aprestan 6to Congreso de la Asociación Latinoamericana de Inmunefectuarse en el Palacio de Convenciones, La Habana, Cub9 y 13 de diciembre del presente año.

Este evento se ha concebido para que coincida con la3er Congreso Cubano de Inmunología, oportunidad proconocer sobre los avances en la investigación, tratamiende enfermedades en Cuba.

Se espera que profesionales provenientes de más de 40 pen este cónclave regional que contará también con prestigiosos especialistas de otras latitudes.

Por la importancia y la calidad científica de las contribucdebatirán, VacciMonitor ha considerado oportuno compilaespecial, los resúmenes de los trabajos que serán preseHavana 2002.

ORGANIZING COMMITTEE / COMITE ORGANIZADOR

Presidents / PresidentesJorge V. Gavilondo (Cuba; President / Presidente, ALAI); Gustavo Sierra (Cuba; E-mail: [email protected]

Vicepresidents / VicepresidentesOliver Pérez (Cuba; General Secretary / Secretario General, ALAI, SCI); Clelia RieVice-president ALAI / Vice-presidente ALAI); Alberto Nieto (Uruguay; Past PresidPresidente Anterior ALAI)

Secretariat (alphabetical order) / Secretariado (orden alfabético)Reinaldo Acevedo; Marta Ayala (Treasurer ALAI / Tesorera ALAI); Julio Balboa; Bracho;Mónica Bequet; Osmir Cabrera; Judith M. del Campo; Maribel Cuello; Al(Conventions Center / Palacio de Convenciones); Danay Gil; Miriam Lastre (TreaTesorera SCI); Tamara Rodríguez; Caridad Román (Havanatur SA)

Support / AseguramientoCarlos Taboada Caridad Zayas Carlos Corcho

National Advisory Committee / Comité Asesor NacionalAgustín Lage; Carlos Silva; Antonio González-Griego; Catalino UstarizRuben RodConsuelo Macías; Sergio Arce; Alina Alerm; Luis Fonte;Jose L Fernández-Yero;MAlonso Gustavo Kourí; Jose M. Ballester;Rolando Pérez;Eduardo Pentón;Rosa Is

Regional and International Scientific Advisory Committee / Comité CieRegional e InternacionalFernando Goñi (Uruguay); Armando Peréz Puigbó (Venezuela); Alberto Nieto (UrOrtiz (Mexico); Marianna Newkirk (Canada); Ethel García Latorre; (México/MéxicLouis (WHO);Margarita Brizuela (Paraguay); Mohamed Daha (The Netherlands/HCarlos Aguillón (Chile);Josef Smolen (Austria); Arturo Ferreira (Chile); Genevieve(France/Francia); Jorge Allende (RELAB); Anders Orn (Sweden/Suecia); Livia LusFritz Melchers; Switzerland/Suiza); Carlos A. Fossati (Argentina); Ricardo CardoOscar Grau (RELAB); Luis F. García (Colombia); Rodrigo Correa de Oliveira (BrazPellegrini (PAHO/OPS); Jorge Kalil (Brazil); George das Reis (Brazil); Alejandro ALeopoldo Santos (Mexico/México); José A Chabalgoity (Uruguay); Harmut Peter(Germany/Alemania); Jacob Natvig (Norway); Clelia Riera (Argentina)

para asistir alología (ALAI), aa, entre los días

celebración delpicia para dar ato y prevención

aíses se den citala presencia de

iones que allí ser en este númerontados en ALAI

President /

ra (Argentina;ent ALAI /

Gustavoicia Garcíasurer SCI /

ríguez-Gavaldá;aria Eugenia

la

ntífico Asesor

uguay); Vianneyo);Jacquesolanda);Juan Milon;tig (Argentina);

na (Colombia);il/Brasil); Albertofani (Chile);

mailto:[email protected]

http://www.finlay.edu.cu/

RESÚMENES

PLENARY CONFERENCES

Gustavo Sierra (Cuba) First effective vaccine against B meningococcal disease based on aproteoliposome structure

Philippa Marrack (USA) The courtship between MHC and the T-cell receptor

Parallel Plenary Conferences (Tuesday 10, Morning)

Agustin Lage (Cuba) Immunoregulation and cancer: the hurdles of complexity (Room 3)

Louis Du Pasquier(Switzerland) Origin and evolution of the vertebrate immune system (Room 4)

Parallel Plenary Conferences (Tuesday 10, Afternoon)

Masayuki Miyasaka(Japan)

Molecular determinants controlling tissue-specific lymphocyte homing -dogmas and enigmas (Room 3)

Anders Örn (Sweden) Defining factors necessary to initiate and maintain chronic inflammatorydisorders in murine Chagas´ Disease (Room 4)

Parallel Plenary Conferences (Wednesday 11, Morning)

Jacques Louis(Switzerland)

The murine model of infection with L. major as a tool to study geneticdifferences in Th subset development (Room 3)

Marianna Newkirk(Canada)

The Rheumatoid Factor response in infection and autoimmunity (Room4)

Parallel Plenary Conferences (Wednesday 11, Afternoon)

Mohamed Daha (TheNetherlands)

Innate immunity and the complement system in autoimmune disease(Room 3)

Paul Kincade (USA) Identification of the earliest lymphocyte precursors in bone marrow ofmouse and man (Room 4)

Parallel Plenary Conferences (Thursday 12, Morning)

Nikolay Petrovsky(Australia) Temporal compartmentalisation of the immune response (Room 4)

Parallel Plenary Conferences (Thursday 12, Afternoon)

Jorge Kalil (Brazil) Immunopathology of rheumatic heart disease (Room 3)

Christopher Rudd (UK) Role of adaptors in TcR and co-receptor signaling (Room 4)

Parallel Plenary Conferences ( Friday 13, Morning)

Jorge V. Gavilondo(Cuba) Recombinant therapeutic antibodies (Room 3)

Lindsay Dent (Australia) Eosinophils in health and disease (Room 4)

Closing Keynote Address (Friday 13, Afternoon)

Henry Metzger (USA) Policy for science, science for policy

ORAL SESSIONSTUMOR IMMUNOLOGY AND IMMUNOTHERAPY

1. Nikolay Petrovsky (Australia) Computational modeling and prediction systems in clinical andexperimental immunology

2. W. H. Fridman (France) Tumor immunological microenvironment: prognostic and therapeuticvalue

3. Catherine Sautes-Fridman (France) Expression and biological roles of Fc gamma receptors inhuman metastatic melanoma

4. Luis E. Fernández (Cuba) Acetylated and glycolilated GM3 cancer vaccine: an update 5. Jose A. Chabalgoity (Uruguay) Designing new immunotherapies for cancer using liveattenuated salmonella as a vector for DNA vaccines

6. Laszlo Radvanyi (Aventis-Pasteur) New antigens and vectors for therapeutic vaccination againstbreast cancer and tumor angiogenesis

7. Ana M. Vázquez (Cuba) Evidences of an idiotypic network in the Neu Gc-containing gangliosidesystem: preclinical and clinical data

8. Cornelis Melief (The Netherlands) Precision guiding of cytotoxic T lymhocytes responses forcancer therap

9. Tania Crombet (Cuba) Epidermal growth factor based cancer vaccine for non-small cell lungcancer therapy: report from a phase I scale up trial

10. Flavio Salazar Onfray (Chile) Detection of anti melanoma specific CTL in PBMC from melanomapatients treated with autologous dendritic cells loaded with tumor cell extracts

11. Giselle Suárez (Cuba) Phase I clinical trial of the ganglioside cancer vaccine N-Acetyl-GM3/VSSP/Montanide ISA 51 in advanced breast cancer patients

12. Marie C. Bene (France) Immunophenotyping of leukemias 13. Gilbert C Faure (France) Tobacco exposure: local inflammation or acquired immune deficiency 14. Carlos Barbas III (USA) Chemical approaches to cancer therapeutics 15. James W. Larrick (USA) Novel approaches to reverse resistance to apoptosis in cancer 16. Mayra Ramos (Cuba) 99mTc labeled anti-human EGF receptor antibody (ior EGF/R3) in patientswith tumors of epithelial origin

17. Tania Crombet (Cuba) Use the anti EGF receptor antibody h-R3 in combination withradiotherapy in the treatment of advanced head and neck cancer

18. Pedro López-Saura (Cuba) Interferons and neoplasia in Cuba 19. AS Schanoski et al. (Brazil) WALKER 256 TUMOR MHC CLASS I EXPRESSION DURING THESHIFT FROM "A" VARIANT INTO THE IMMUNOGENIC "AR" VARIANT. SOP

20. L Alaniz et al. (Argentina) CD44-HYALURONIC ACID INTERACTION MODULATESMETALLOPROTEINASES IN A T CELL MURINE LYMPHOMA AND IN INFLAMMATORYLEUKOCYTES. SOP

21. MC Anazetti et al. (Brazil) TREATMENT OF LEUKEMIC CELLS (HL60) WITH DIMETHYLAMIDE-CROTONIN TRIGGERS APOPTOSIS DEPENDENT OF CASPASES -2 AND -9, BACTIVATION.SOP

IMMUNOLOGY OF PARASITE DISEASES

1. Manoel Barral Netto (Brazil) Immunology of human leishmaniasis 2. Genevieve Milon (France) Parasitism, a rapid and renewed cross talk between parasites and theimmune system of their hosts: the example of Leishmania spp.

3. Edgar Carvalho (Brazil) The role of host and parasite factors in the development of tegumentaryleishmaniasis

4. Aldina Barral (Brazil) Molecular epidemiology of human leishmaniasis: natural immune responsesagainst saliva proteins derived from the insect vector

5. CM Trujillo et al. (Colombia) CELL EXPRESSION OF COSTIMULATORY MOLECULES NODIFFERS IN PATIENTS WITH LOCALIZED CUTANEOUS LEISHMANIASIS AND ENDEMICALLY

EXPOSED ASYMPTOMATICS. SOP 6. S Télles et al. (Venezuela) EXPRESSION OF PEPTIDE-HLA COMPLEXES IN INFECTEDMACROPHAGES WITH Leishmania Braziliensis. SOP

7. H Goto et al. (Brazil) IMMUNOPATHOGENESIS OF GLOMERULONEPHRITIS IN VISCERALLEISHMANIASIS (VL) INVOLVES CD4+ T CELLS, IMMUNOGLOBULIN AND MODULATION OFAPOPTOSIS. SOP

8. Rose Leke (Cameroon) Malaria during pregnancy: diagnosis and immune responses 9. Arturo Ferreira (Chile) Trypanosoma cruzi Calreticulin: some immunomodulatory properties

10. A Ruiz Espinosa et al. (Cuba) CONSTRUCTION AND EVALUATION OF IMMUNOGENICITY ANDINDUCED PROTECTION IN BALB/C MICE IMMUNIZED WITH A GENOMIC LIBRARY OFEXPRESSION OF TRYPANOSOMA CRUZI. SOP

11. JC Sepulveda-Arias et al. (Colombia-Germany) STUDIES ABOUT IMMUNE RESPONSE IN RATSINFECTED WITH Toxoplasma gondii VIA MILK. SOP

12. A. Rodríguez et al. (Cuba) SIGNIFICANT PROTECTIVE EFFECTS OF NAKED DNA BASEDIMMUNIZATION FROM LETHAL TOXOPLASMOSIS IN MICE. SOP

13. Rodrigo Correa (Brazil) Mechanism of resistance and pathology in Schistosoma nansoniinfection

14. Miguel Stadecker (USA) Schystosomiasis: a helminthic disease caused and shaped by the hostsimmune response

15. David Pritchard (UK) The immunological challenge posed by human hookworm infections, andthe quest for vaccines

16. G Ferragut et al. (Uruguay) ROLE OF IL-4 IN EXPERIMENTAL INFECTION BY THE HELMINTHEchinococcus granulosus. SOP

17. A Olivos-García et al. (Mexico) AMEBIC CYSTEINE PROTEINASE 2 (EhCP2) PLAYS EITHER AMINOR OR NO ROLE IN TISSUE DAMAGE IN ACUTE EXPERIMENTAL AMEBIC LIVER ABSCESSIN HAMSTERS. SOP

18. Luis Fonte Galindo et al. (Colombia) INTESTINAL AMEBIASIS. IMMUNOLOGICAL ANDBIOMOLECULAR DEMONSTRATION OF THE OVERESTIMATION OF A HEALTH PROBLEM. SOP

19. M del P Jiménez et al. (Colombia) DIFFERENTIAL PHAGOCYTIC CAPACITY OF Nramp1 GENECONGENIC MACROPHAGE LINES TO THE INFECTION WITH CONIDIAS OF ParacoccidioidesBraziliensis. SOP

IMMUNOLOGY OF VIRAL DISEASES

1. Verena Muzio (Cuba) Hepatitis B prophylactic vaccines: realities and new perspectives 2. Eduardo Pentón (Cuba) Therapeutic vaccine approaches to Hepatitis B infection 3. Santiago Dueñas (Cuba) Development of therapeutic vaccines for Hepatitis C 4. Antonio González Griego (Cuba) Considerations on diagnostic, prognostic and prophylaxis-therapeutic intervention in Hepatitis type B

5. Hugo Nodarse (Cuba) Treatment of viral diseases with Interferon in Cuba 6. J Marante et al. (Cuba) IMPROVEMENT OF HCV-SPECIFIC IMMUNE RESPONSES USING ANEW VECTOR OF THE pMAE PLASMID SERIE. SOP

7. E Esquivel et al. (Mexico) ANALYSIS OF B AND T CELL ACTIVATION IN MESENTERIC LYMPHNODES FROM MICE INFECTED WITH ROTAVIRUS. SOP

8. Elopy Sibanda (Zimbabwe) HIV: diagnostic, clinic, and therapeutic aspects in Africa 9. Carlos Duarte (Cuba) Induction of a Th1, CTL mediated immune response against HIV-1chimeric proteins with DNA and poxviral vectors

10. Barbara Ensoli (Italy) Novel approaches for HIV/AIDS vaccine development: from basic scienceto human trials

11. D Vázquez-Blomquist et al. (Cuba) MODIFIED VACCINIA VIRUS ANKARA (MVA) PRIMING ANDFOWLPOX VIRUS BOOSTER ELICIT STRONGER CTL RESPONSE IN MICE AGAINST AN HIV-1EPITOPE THAN DNA-POXVIRUS PRIME-BOOST APPROACH. SOP

12. A Alvarez et al. (Cuba) VIRAL LOADS AND PHENOTYPIC MARKERS OF HIV PROGRESSION INCUBAN PATIENTS. SOP

13. E Iglesias et al. (Cuba) IMMUNIZATION WITH MAPs COUPLED TO CARRIERS: INFLUENCE OFTHE EPITOPIC DENSITY AND PRE-EXISTING IMMUNITY TO THE CARRIER. SOP

14. V Kourí et al. (Cuba) KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS (KSHV)SEROPREVALENCE IN CUBAN POPULATIONS. SOP

15. Gustavo Kouri (Cuba) Dengue. Situation in Latin America and the Caribbean - 2002 16. Eric Martínez (Cuba) Pathogenesis of Dengue Hemorrhagic Fever 17. Guadalupe Guzmán (Cuba) Dengue vaccines, advances and challenges 18. G Mellado Sánchez et al. (Mexico) EVALUATION OF IMMUNE RESPONSE OF INFECTEDDENGUE PATIENTS TO RECOMBINANT NS1 AND E PROTEINS. SOP

19. MMB Moreno-Altamirano et al. (Mexico) GENE EXPRESSION IN HUMAN MACROPHAGESINFECTED WITH DENGUE VIRUS. SOP

20. AB Pérez et al. (Cuba-EEUU) SERUM LEVELS OF IL-12, IL-10, RANTES AND NITRIC OXIDE INDENGUE VIRUS INFECTED PATIENTS. SOP

21. B Sierra et al. (Cuba) THE RECOMBINANT DEN 2 ENVELOPE B DOMAIN ELICITS A STRONGSEROTYPE SPECIFIC LYMPHOPROLIFERATIVE RESPONSE IN MICE. SOP

IMMUNOLOGY OF BACTERIAL DISEASES

1. Stitaya Sirisinha (Thailand) Dendritic cell maturation and cytokine production induced byBurkholderia (pseudomonas) pseudomallei

2. Narinder Mehra (India) Cytokine polarization in mycobacterial infections: MHC influences3. Stanley Ress (South Africa) Immune response to neonatal BCG vaccination4. David Pritchard (UK) Immune modulation by bacterial quorum sensing molecules, and their

application to immunological disease5. Vincent Wilson (UK) Further studies on the acute effect of bacterial 'quorum-sensing'

molecules on porcine coronary arteries6. Narinder Mehra (India) Extreme MHC diversity and its implications on vaccination protocols7. R Pellegrino et al. (Uruguay) MrpA FIMBRIAL PROTEIN AS A PROTECTIVE ANTIGEN AGAINST

URINARY TRACT INFECTIONS. SOP8. Dietrich Kabelitz (Germany) Role of human gamma delta T lymphocytes in disease9. Vincent Wilson (UK) FMLP produces vasoactive effects in human and porcine blood vessels10. Oliver Pérez (Cuba) Immunological response induced by relevant protective bacterial antigens11. Marta González (Cuba) Immunogenicity, potency, and safety of an adsorbed trivalent

Leptospira vaccine12. Luis García (Cuba) Advances in the research of Cuban Cholera vaccine13. Luis Riverón (Cuba) Vi polysaccharide typhoid vaccine14. Luis F. García (Colombia) Consequences of Mycobacterium tuberculosis (Mtb) infection on

macrophage functions15. Idrián García (Cuba) Use of recombinant human interferon gamma in patients with multidrug-

resistant tuberculosis16. Armando Acosta (Cuba) New strategies for tuberculosis vaccine development17. D Gil et al. (Colombia) MYCOBACTERIAL-INDUCED NECROSIS AND APOPTOSIS IN

MACROPHAGES FROM PATIENTS WITH TUBERCULOSIS (TB) AND HEALTHY CONTROLSDEPEND ON TNF-alfa/IL-10 BALANCE. SOP

18. B Rivas-Santiago et al (Mexico-USA). INDUCTION OF HUMAN b-DEFENSIN 2 mRNAEXPRESSION BY MYCOBACTERIUM TUBERCULOSIS IN A HUMAN LUNG EPITHELIAL CELLLINE. SOP

19. B Ortiz et al. (Colombia). ROLE OF CD14, MANNOSE RECEPTOR (MMR), SCAVENGERRECEPTOR (ScR) AND TOLL-LIKE RECEPTOR 2 (TLR2) IN Mycobacterium tuberculosis-INDUCED MACROPHAGE APOPTOSIS. SOP

20. AVE Capozzo et al. (Argentina) DEVELOPMENT OF GENETIC VACCINES AGAINST HEMOLYTIC

UREMIC SYNDROME (HUS). SOP21. Sandra Bajaña-Miranda et al. (Mexico). CUTANEOUS LANGERHANS DENDRITIC CELLS AND gd

T CELLS IN A MURINE MODEL OF LEPROSY: IN VIVO ANALYSIS. SOP22. RM Salazar González et al. (Mexico). EVALUATION OF THE IMMUNE RESPONSE TO PORINS

FROM Salmonella typhi IN HUMANS. PHASE 1 STUDY. VACCINE AGAINST TYPHOID FEVER.SOP

23. M Lastre et al. (Cuba-Italy). NEUTROPHILS IN THE INDUCTION OF IMMUNE RESPONSE ANDEFFECTOR CELA MENINGITIDIS B. SOP

ADJUVANTS

1. Johan Hoebeke (France) What can we learn from the structure of antibody-peptide complexes? 2. Wolfram Metzger (Germany) Attenuated Salmonella as carriers for an anti Helicobacter vaccinein mouse and man

3. José A López (Australia) Optimising a blood DC preparation for immunotherapy 4. Gerardo E Guillén (Cuba) Immunologic evaluation of a DTP-HB vaccine formulation for nasaladministration

5. Jim Koropatnick (Canada) Metallothionein and innate activation of primary human and mousemonocytes

6. Osmir Cabrera (Cuba) Conjugation as a possible solution to antigens with low immunogenicity

IMMUNODEFICIENCIES

1. Harmut Peter (Germany) Common variable immunodeficiency: a new classification andmolecular definition of new subsets

2. Teresa Español (Spain) Diagnosis of the molecular defects causing primary immunodeficiencydiseases

3. Ricardo Sorensen (Argentina) Specific antibody deficiencies: implications for the developmentof the humoral immune system

4. Oscar Porras (Costa Rica) MHC class II deficiency 5. Julia Palma (Chile) Pediatric Hematopoyetic Stem Cell Transplantation (HSCT) in primaryimmunodeficiency diseases

6. Teresa Español (Spain) Update on therapy for primary immunodeficiency diseases

IMMUNOLOGY AND REPRODUCTION

1. Petra Clara Arck (Germany) Immunobiology of implantation and occult pregnancy loss 2. Ricardo A. Margni (Argentina) Asymmetric antibodies: role in the maintenance of a non-conflictive mother-fetus relation

3. Gerard Chaouat (France) Cytokines in pregnancy and implantation/early abortion: re-examiningthe Th1/Th2 paradigm

4. Ana Claudia Zenclussen (Argentina) Introducing a novel mouse model for pre-eclampsia 5. Li via Lustig (Argentina) Immunoregulation and autoimmunity of the testis: pathogenesis ofexperimental autoimmune orchitis

6. J Puente et al. (Chile) FUNCTIONAL AND PHENOTYPIC RESPONSE OF THE HUMAN NK CELLSIN NORMAL AND PATHOLOGICAL PREGNANCY. SOP

AUTOIMMUNITY AND AUTOIMMUNE DISEASES

1. Jorge Kalil (Brazil) Antigen recognition and trimolecular complex in post-infectious autoimmunedisease

2. Eli Sercarz (USA) Public, drived T cell clones as the cause of autoimmunity in EAE and IDDM 3. Xian-hao Xu (China) Recent advances of study on Myasthenia Gravis in China 4. Ethel García Latorre (Mexico) Process and presentation of the rHSP60 from Klebsiellapneumoniae in ankylosing spondylitis

5. Johan Hoebecke (France) Autoantibodies against G protein coupled cardiovascular receptors:how do they interfere with receptor function?

6. F Zambrano-Zaragoza et al. (Mexico) RECOGNITION OF THE 117-125 PEPTIDE OF THE HSP60FROM Klebsiella pneumoniae BY CD8 T CELLS FROM ANKYLOSING SPONDYLITIS PATIENTS.SOP

7. F González et al. (Chile) THE -308 POLYMORPHISM IN THE PROMOTER REGION OF TUMORNECROSIS FACTOR GENE AND EX VIVO LIPOPOLYSACCHARIDE-INDUCED TNF EXPRESSIONIN PATIENTS WITH AGGRESSIVE PERIODONTITIS AND/OR TYPE 1 DIABETES MELLITUS. SOP

8. Moncef Zouali (France) Immune receptor signaling and autoimmunity 9. Enrique Montero (Cuba) Therapeutic immunosuppression and immunodiagnosis of autoimmunediseases based on an anti-CD6 monoclonal antibody

10. Nikolai Petrovsky (Australia) Pathogenesis of type 1 diabetes: dominant pathway of beta cellapoptosis and prevention of immune mediated beta cell destruction

11. Clelia M. Riera (Argentina) Experimental autoimmune prostatitis: a model of chronic nonbacterium human prostatitis?

12. Constantin Bona (USA) Molecular and genetic studies on the role of IL-4 in fibrosis 13. X Hernández et al. (Cuba) EVALUATION OF THE TOXICITY OF THE HUMANIZEDMONOCLONAL ANTIBODY T1HT IN PATIENTS WITH RHEUMATOID ARTHRITIS. SOP

14. M Sospedra et al. (Spain-USA) UNBIASED IDENTIFICATION OF ANTIGEN SPECIFICITIES OFCEREBROSPINAL FLUID-INFIL MULTIPLE SCLEROSIS. SOP

SIGNAL TRANSDUCTION - CELL INTERACTIONS

1. Hannes Stockinger (Austria) Membrane microdomains in signal transduction of immune cells 2. Mario Rosemblatt (Chile) Dendritic cells as regulators of lymphocyte homing 3. Henry Metzger (USA) Quantitative analysis of signal transduction 4. Leopoldo Santos (Mexico) CD38 uses the classical signal transduction pathway PLC-gamma 2,pKC, and nF-kB to induce survival and proliferation of mature B cells

5. John Kappler (USA) The role of Bcl-2 related proteins in T-cell death 6. Carlos Rosales (Mexico) PI 3-K and ERK are recruited for Fc receptor-mediated phagocytosisduring monocyte-to-macrophage differentiation.

ANTIGEN PRESENTATION - TRANSPLANTATION

1. Laurence Boumsell (France) International workshops and conferences on CD molecules: past,present, and future

2. Nelson Fernández (UK) Models of cell surface expression of MHC Class II and its importance inthe immunological synapse

3. Cristina Cuturi (France) Regulatory cells and tolerance in transplantation 4. Ignacio Anegón (France) Costimulatory blockade and tolerance in allotransplantation using genetransfer

5. Josef Brock (Germany) Alloreactive EGFP-engineered T lymphocytes in a rat kidneytransplantation model

6. D Sauma et al. (Chile) THE DECREASE ON T CELL COUNTS AFTER A SINGLE DOSE OFIMMUNOSUPPRESSIVE DRUGS IN RENAL TRANSPLANT PATIENTS CAN BE ASCRIBED TO ALOW DOSE OF PREDNISONE. SOP

IMMUNOLOGY OF ALLERGIC DISEASES

1. Rudolf Valenta (Austria) Recombinant allergen-based strategies for diagnosis and therapy ofIgE-mediated allergies

2. Momtchilo Russo (Brazil) Oral tolerance prevents the development of airway hyperactivity andTh2-associated allergic responses in prototypic murine models of experimental asthma

3. Ruben Rodriguez-Gavalda (Cuba) Natural history, treatment, and management of childhoodasthma

4. Alina Alerm (Cuba) Immune response against vaccine antigens in asthmatic patients 5. Sabine Flicker (Austria). A grass polen allergen-specific human IgE antibody recognizingimmunoglobulin-like domains

6. Alexis Labrada (Cuba-Colombia) Characterization of rBlo t 13, recombinant allergen from Blomiatropicalis using monoclonal antibodies.

7. TG Naidu et al. (Brazil) A COMPARATIVE EVALUATION OF SERUM EOSINOPHIL CATIONICPROTEIN (S-ECP) AND TOTAL BLOOD IgE AS DIAGNOSTIC PARAMETERS IN PEDIATRICASTHMA. SOP

8. L. Calderón et al. (Cuba) LIPOSOME ENCAPSULATION OF THE MAJOR ALLERGENS OFDermatophagoides siboney FOR SPECIFIC IMMUNOTHERAPY. SOP

9. JL Aguilar Olano et al. (Peru). ETIOPATHOGENIC ROLE OF FUME OF FISH'S FLOURFACTORIES IN THE DEVELOPMENT OF ALERGIC MANIFESTATIONS BY CHILDRENACHANCAY, LIMA, PERU. SOP

IMMUMUNOTECHNOLOGY

1. Luis Javier González (Cuba) Advances in proteome technology 2. James W. Larrick (USA) New approaches for design of gene chips 3. Angel Oñate (Chile) DNA vaccine in Brucella abortus 4. Alexei Licea (Mexico) Anti-idiotypic chimeric antibodies as an anti-scorpion toxin vaccine 5. Alexei Licea (Mexico) Shark chimeric antibodies 6. Cristina Mateo (Cuba) A new method to reduce immunogenicity of chimeric monoclonalantibodies

7. Gertrudis Rojas (Cuba) Phage display libraries as sources of human antibodies: from basics toclinics

8. Gregg Silverman (USA) Phage-display engineering of magic bullets for induction of in vivo VHtargeted apoptotic deletion of B-cells in mice and non human primates

9. James W. Larrick (USA) Taczyme: a new means to generate and affinity mature antibodies 10. Merardo Pujol (Cuba) Tobacco as a model plant for recombinant antibody expression

11. Rodolfo Valdés et al. (Cuba) IMMUNOPURIFICATION OF THE HEPATITIS B SURFACE ANTIGENUSING A PLANT-DERIVED HBsAg-SPECIFIC ANTIBODY. SOP

12. O Gires et al. (Germany) DIRECT IDENTIFICATION OF TUMOR ANTIGENS BY AUTOLOGOUSANTIBODY SCREENING. SOP

13. P Vargas et al. (Chile) DENDRITIC CELL IMMUNIZATION IMPROVES PRODUCTION OFMONOCLONAL ANTIBODIES AGAINST THE REGULATOR OF MHC CLASS II EXPRESSION(CIITA). SOP

CYTOKINES - INFLAMATION

1. Juan C. Aguillón (Chile) Genetic polymorphism of cytokines: implications on susceptibility orresistance to diseases

2. Sergio Romagnani (Italy) Pleiomorphic role of CXCR3 and its ligands 3. Ralf Schumann (Germany) Pathogen-associated molecular patterns (PAMPs) and the host'sinnate immune recognition system

4. Douglas Golenbock (USA) Lessons from Drosophila: the LPS receptor 5. Manuel Araña (Cuba) Anti LPS peptides and cytokine regulation in sepsis 6. Horacio Serra (Argentina) SLC (CCL21): much more than a constitutive chemokine 7. M Kurte et al. (Chile) A SYNTHETIC PEPTIDE HOMOLOGOUS TO THE FUNCTIONAL DOMAINOF HUMAN INTERLEUKIN 10 DOWNREGULATES THE EXPRESSION OF THE MHC CLASS I

ALPHA CHAIN AND TAP 1/2 IN HUMAN MELANOMA CELLS. SOP 8. John Hiscott (Canada) IFN and NF-kB signaling pathways and the regulation of innate immunity 9. Silvio Perea (Cuba) Abrogation of the interferon (IFN) signaling pathways by humanpapillomavirus (HPV) type-16

10. Celia Fernandez (Cuba) NF-kB down regulation is a common target for the inhibition of TNFproduction and HIV replication by the DLE

11. Pedro Porrero (Cuba) Interferon-alpha in nervous system disorders 12. P A Rojas et al. (Peru-Germany) EFFECT OF AN EXTRACT OF Uncaria tomentosa (UÑA DEGATO) ON THE PRODUCTION OF THE TUMORAL NECROSIS FACTOR - ALPHA IN A MODELIN VIVO AND ITS ACTION LIKE AN ANTI-INFLAMMATORY AGENT IN VITRO. SOP

IMMUNODIAGNOSTICS

1. Rene Robaina (Cuba) Creating a sustainable diagnostic network with national scope: the caseof the SUMA system in Cuba

2. Luis Sorell (Cuba) Immunodiagnosis of celiac disease using fast visual tests 3. Mercedes Lopez (Chile) Immunohistochemical diagnosis of uveal malignant melanoma usingMelanocortin 1 Receptor (MC1R) specific antibodies

4. Anselmo Otero (Cuba) Immunoanalytic tools for the evaluation of enzymatic function. AcatELISA for detection of HIV protease inhibitors.

5. B Velázquez et al. (Uruguay) OPTIMIZATION OF RECOMBINANT STREPTOLYSIN-OEXPRESSION AND ANALYSIS OF FINAL PRODUCT FORMULATIONS SUITABLE FORIMMUNODIAGNOSIS. SOP

6. M Hernández et al. (Cuba) CHIMERIC SYNTHETIC PEPTIDES CONTAINING TWOIMMUNODOMINANT EPITOPES FROM THE GAG P19 PROTEIN AND THE ENVELOPE GP46GLYCOPROTEIN FOR THE IMMUNODIAGNOSIS OF HTLV-II VIRUS INFECTION. SOP

7. RA Rivero et al. (Cuba) MOUSE MONOCLONAL ANTIBODIES AGAINST ABO BLOOD GROUPANTIGENS IN CUBA: ITS EVALUATION IN THE 4TH INTERNATIONAL WORKSHOP. SOP

8. C Macías et al. (Cuba) ENDOTHELIAL ADHESION MOLECULES ICAM-1, VCAM-1 AND E-SELECTIN IN PATIENTS WITH ACUTE CORONARY SYNDROME. SOP

VETERINARY IMMUNOLOGY

1. Manuel Rodriguez (Cuba) The Cuban experience in the control of Boophilus spp. by the anti-tickvaccine GavacTM

2. Patricia Zamorano (Argentina) Bovine herpes virus protein from plants infected withrecombinant tobacco mosaic virus possesses authentic antigenicity

3. A Soutullo et al. (Argentina) IMMUNE RESPONSE OF THE EQUINE INFECTIOUS ANEMIADISEASE VIRAL GP 45 PROTEIN TO A SYNTHETIC PEPTIDE IN MICE. SOP

4. TA. Cruz (Mexico) APOPTOSIS IN LUNGS OF PIGS INTRATRACHEALLY INOCULATED withMycoplasma hyopneumoniae. SOP

5. J. Casas et al. (Mexico) COMPARATIVE STUDY OF THE IMMUNE RESPONSE OF FIVEDIFFERENT SPECIES OF TILAPIA (Oreochromis). SOP

6. R Rivers et al. (Chile) DNA VECTORS FOR Brucella abortus. SOP 7. TG Naidu. (Brazil) LYSOSOMAL DEGRANULATION IN POLYMORPHONUCLEAR NEUTROPHILS:A NOVEL MECHANISM OF SURVIVAL OF PATHOGENIC b-HEMOLYTIC Staphylococcus aureusIN THE BOVINE MAMMARY GLAND. SOP

8. AP West Jr, PJ Bjorkman. (USA) CLONING AND CHARACTERIZATION OF THE CHICKEN YOLKSAC IGY RECEPTOR. SOP

POSTER SESSIONSIMMUNOLOGY OF BACTERIAL DISEASES I

1. HLA CLASS II GENES POLIMORPHISMS IN DRUG SENSITIVE AND DRUG RESISTANTPULMONARY TUBERCULOSIS IN MEXICANS PATIENTS. A Camarena Olvera, A JuárezCisneros, A Aquino Gálvez, D Castillo Sánchez, R Falfán Valencia. (MEXICO)[email protected].

2 2. DEVELOPMENT OF GENETIC VACCINES AGAINST HEMOLYTIC UREMIC SYNDROME (HUS).AVE Capozzo, C Ibarra, V Pistone Creydt, G Dran, G Fernández, M Isturiz, MS Palermo.(ARGENTINA). [email protected]

3 3. TNFa, IFNg AND IL-10 GENE POLYMORPHISMS AND CYTOKINE PRODUCCION IN PATIENTSWITH TUBERCULOSIS (TB) AND HEALTHY CONTROLS. M Henao, S París, L F García.(COLOMBIA) [email protected]

4 4. HIGH LEVELS OF NITRIC OXIDE CORRELATES WITH MYCOBACTERIUM TUBERCULOSISINHIBITION OF IFNg-INDUCED MHC CLASS II EXPRESION IN MURINE MACROPHAGES. JLJaramillo, GM Vásquez, LF García, LF Barrera. (COLOMBIA). [email protected]

5

5. EXPRESSION OF TOLL-LIKE RECEPTOR 2 (TLR2) IN DIFFERENT CIRCULATING CELLPOPULATIONS AND COMPARISON OF CD14+TLR2+ BLOOD MONOCYTES IN PATIENTSWITH TUBERCULOSIS AND HEALTHY CONTROLS. MC Ruiz, M Rojas, LF García. (COLOMBIA)[email protected]

6

6. MONOCYTES AND NEUTROPHILS FROM TUBERCULOSIS PATIENTS ARE INSENSITIVE TOANTI-INFLAMMATORY EFFECTS TRIGGERED BY A PROTOTYPIC N-FORMYL PEPTIDE (FMLP).M Beigier-Bompadre, M Alemán, P Barrionuevo, MC Franco, CJ Rubel, MS Palermo, E Abbate,MC Sasiain, MA Isturiz. (ARGENTINA). [email protected]

7 7. ROLE OF POLYMORPHISMS OF THE CD14 GENE PROMOTER IN TUBERCULOSIS. C Fonseca, EPacheco, L Garcia, M Arias. (COLOMBIA) [email protected]

8 8. MODULATION OF SCAVENGER RECEPTORS (ScR) IN MONOCYTES FROM HEALTHYCONTROLS AND PATIENTS WITH TUBERCULOSIS (TB) BY MYCOBACTERIAL DERIVATIVES.LG León, M Rojas, LF García. (COLOMBIA) [email protected]

9 9. BYSTANDER MACROPHAGES REMOVE Mycobacterium tuberculosis-INFECTEDMACROPHAGES AND INHIBIT THE INTRACELLULAR GROWTH OF Mycobacteriumtuberculosis. LG León, M Rojas, LF García. (COLOMBIA) [email protected]

0

10. ROLE OF CD14, MANNOSE RECEPTOR (MMR), SCAVENGER RECEPTOR (ScR) AND TOLL-LIKERECEPTOR 2 (TLR2) IN Mycobacterium tuberculosis-INDUCED MACROPHAGE APOPTOSIS. BOrtiz, M Rojas, LF García. (COLOMBIA) [email protected]

11. SPECIFIC PROLIFERATION OF CD4+ AND CD8+ T CELLS AGAINST Brucella abortus RB51ANTIGEN. M C Moreno-Lafont, V Paredes-Cervantes, A Estrada-Aguilera, R López-Santiago.(MEXICO). [email protected]

2

12. EPIDEMIOLOGY OF MUCOCUTANEOUS INFECTIONS IN THE RECURRENT INFECTIONSYNDROME. JC Orrego, CJ Montoya, RD Gómez, PJ Patiño G., ME Vargas, JL Franco R., DGarcía de O., JC Wolf. (COLOMBIA)

3

13. MrpA FIMBRIAL PROTEIN AS A PROTECTIVE ANTIGEN AGAINST URINARY TRACTINFECTIONS. R Pellegrino, P Scavone, U Galvalisi,V Sosa, L Geymonat, P Zunino. (URUGUAY)[email protected]

4 14. MODULATION OF MYCOBACTERIAL-INDUCED MACROPHAGE APOPTOSIS BY ANTI-MYCOBACTERIAL DRUGS. D Gil, LF García, M. Rojas. (COLOMBIA). [email protected] PDF

5

15. MYCOBACTERIAL-INDUCED NECROSIS AND APOPTOSIS IN MACROPHAGES FROMPATIENTS WITH TUBERCULOSIS (TB) AND HEALTHY CONTROLS DEPEND ON TNF-alfa/IL-10BALANCE. D Gil, LG León, LF García, M Rojas. (COLOMBIA). [email protected]

6

16. EVALUATION OF THE IMMUNE RESPONSE TO PORINS FROM Salmonella typhi IN HUMANS.PHASE 1 STUDY. VACCINE AGAINST TYPHOID FEVER. RM Salazar González, MC MaldonadoBernal, NE Ramirez, J Beltrán Nava, C Tello Winniczuk, M Carrera Camargo, C López Macias, AIsibasi. (MEXICO). [email protected]

7

17. SALIVARY LEVELS OF IgA AND Streptococcus mutans IN PRE-AMAZONIC BRAZILIANPREGNANT WOMEN. R R Maya, M V V Lima, J E Batista , R N M Guerra. (BRAZIL/BRASIL)[email protected]

8

18. OPTIMIZATION OF PRECLINICAL IMMUNIZATION WITH OUTER MEMBRANE VESICLESVACCINE. G Bracho, S Cabezas, J del Campo, M Lastre, T Rodríguez, C Zayas, G Sierra, OPérez. (CUBA). [email protected]

9

19. ENDOGENOUS GLUCOCORTICOID (GC) MODULATE NEUTROPHIL (PMN) FUNCTION IN AMURINE MODEL OF HEMOLYTIC UREMIC SYNDROME (HUS). S Gómez, G Fernández , CRubel, F Alves Rosa, P Barrionuevo, MA Isturiz, MS Palermo. (ARGENTINA)[email protected]

20

20. NEUTROPHILS IN THE INDUCTION OF IMMUNE RESPONSE AND EFFECTOR CELL AGAINSTNEISSERIA MENINGITIDIS B. M Lastre, J Lapinet, G Bracho, C Zayas, M Díaz, G Sierra, MACassatella, and O Pérez. (CUBA-ITALY) [email protected]

2 21. CROSS-REACTIVE ACTIVITY OF ANTIMENINGOCOCCAL HUMAN IMMUNOGLOBULINAGAINST DIFFERENT NEISSERIA MENINGITIDES GROUP B SEROTYPES. BalboaJA, et al.(Cuba). [email protected]

22

22. MYCOBACTERIAL ACYL-O-TREHALOSES MODULATE HUMAN T-CELL RESPONSES IN VITRO.R Saavedra, P Lezama, R Leyva, E Segura, LM López Marín. (MEXICO)[email protected]

23

23. EFFECT OF THE SPLENIC DIALIZABLE EXTRACT (SDE) ON MURINE EXPERIMENTALTUBERCULOSIS, ASSESSED BY DIFFERENTIAL DISPLAY. M Pérez-Tapia, R Ramos-Payán, AFabre-Ruíz, J Rangel-Moreno, R Hernández-Pando, I Estrada-G, S Estrada-Parra S. (MEXICO)[email protected]

24

24. CD28, CD80 AND CD86 EXPRESSION IN SKIN CELLS OF LEPROMATOUS AND TUBERCULOIDLEPROSY PATIENTS. S Navarro, C Guerrero, M Corrales, R López, M Fafutis. (MEXICO)[email protected]

25

25. INDUCTION OF HUMAN b-DEFENSIN 2 mRNA EXPRESSION BY MYCOBACTERIUMTUBERCULOSIS IN A HUMAN LUNG EPITHELIAL CELL LINE. B Rivas-Santiago, C Sarabia, SSchwander, G Diamond, E Sada. (MEXICO-USA/MEXICO-EEUU). [email protected]

26

26. CD8+ T CELLS IMPROVE GROWTH INHIBITION OF MYCOBACTERIUM TUBERCULOSIS (MTB)H37RV IN HUMAN ALVEOLAR MACROPHAGES INFECTED IN VITRO. C Carranza, E Juárez, RHernández, C. Sarabia, K Bobadilla, D Escobedo, J Ellner, E Sada, S Schwander. (MEXICO-USA/MEXICO-EEUU). [email protected]

27

27. MEMORY ANTIBODY RESPONSE AND BACTERICIDAL ACTIVITY INDUCED BY PORINS FROMSalmonella enterica SEROVAR Typhi. I Secundino, L Cervantes, J Beltran, R Salazar, CMaldonado, A Isibasi, C López-Macias. (MEXICO). [email protected]

28

28. DIFFERENTIAL PATTERN OF MITOCHONDRIAL MEMBRANE POTENTIAL (DYm) AndCYTOSOLIC CYTOCHROME C In M. tuberculosis H37Ra- AND H37Rv-INFECTEDMACROPHAGES. E Abarca-Rojano, P. Rosas-Medina, P Zamudio-Cortéz , R Mondragón-Flores,FJ Sánchez-García. (MEXICO). [email protected]

29

29. CELL SIGNALING OF MYCOBACTERIAL-INDUCED MACROPHAGE APOPTOSIS. M Rojas, LFGarcía, M Olivier, B Ortiz, D Gil, LG León. (COLOMBIA-CANADA). [email protected]

30

30. M. tuberculosis CULTURE FILTRATE PROTEINS INDUCE CD95 RELATED APOPTOSIS ONMONOCYTES OF THE THP-1 LINE. R. Mancilla, G. Bernal, P. Espinosa-Cueto, H. Díaz-Silvestre,M.A. Esparza-Cerón, M. Colón-González. (MEXICO) [email protected]

3 31. THE 19 kDa GLYCOLIPOPROTEIN OF Mycobacterium tuberculosis IS A MAJOR ADHESIN FORTHP-1 AND MONOCYTE DERIVED-HUMAN MACROPHAGES. H. Díaz-Silvestre, P. Espinosa-Cueto, G. Bernal, C. Espitia, and R. Mancilla. (MEXICO) [email protected]

32

32. EFFECTS OF MYCOBACTERIAL LIPIDS ON PLEURAL MONONUCLEAR CELLS AND OFPETIVERIA ALLIACEA EXTRACT ON RESPONSE TO BCG IN THE PLEURAL CAVITY. V Cabral,A Rodrigues, E Abi-chacra, E Rodrigues, A Moura. (BRAZIL). [email protected]

33

33. T-CELL PROLIFERATION AND IL-2 LEVELS IN YOUNG HEALTHY HOUSEHOLD CONTACTS OFLEPROMATOUS LEPROSY PATIENTS. M. Pita, A. Santerre, G. Zaitseva, A. Islas. (MEXICO)[email protected]

34

34. THE AP-1 TRANSCRIPTION FACTOR IS PRESENT IN LYMPHOCYTES FROM LL PATIENTS. Ma.R. Huizar, A. Santerre, V. Madrid , O. Peralta , A.E. Islas. (MEXICO). [email protected]

35

35. MEMORY RESPONSE GENERATED IN AFRICAN GREEN MONKEYS AGAINSTPOLYSACCHARIDE C CONJUGATE. Carmenate T, Guirola M, Álvarez A, Caballero E, GonzálezS, Menéndez T, Canaán-Haden L, Guillen G. (CUBA). [email protected]

36

36. COMPARISON OF THE IMMUNE RESPONSE IN MICE AGAINST MENINGOCOCCAL GROUP CPOLYSACCHARIDES CONJUGATE TO THREE CARRIER PROTEINS. Alvarez A, Canaan-HadenL, Carmenate T, Menendez T, Delgado D, Rodes L, Silva R, Guillén G. (CUBA)[email protected]

37

37. IMMUNOGENICITY AND PROTECTIVE CAPACITY OF LEPTOSPIRA INTERROGANSSEROGROUP BALLUM KILLED WHOLE CELL ADJUVANTED VACCINES IN HAMSTERS. AGonzález, Y Rodríguez, Y Valdés, N Batista, JF. Nuñez, JF. Infante, M González. (CUBA)[email protected]

38

38. IMMUNOGLOBULIN PREPARATION AGAINST LPS OF PSEUDOMONAS AERUGINOSASEROTYPE O11. A Moya, L Joó, A Rodrígruez, J Hernández Machín, J Hernández, JFAlmenares, D Berrios, Z Rodríguez, A Cádiz, SC Esnard. (CUBA). [email protected]

39

39. EVALUATION OF THE SPECIFIC HUMORAL IMMUNE RESPONSE IN MICE IMMUNIZED WITHAN EXPRESSION GENOMIC LIBRARY OF MYCOBACTERIUM TUBERCULOSIS. A Acosta, ZDíaz, K Hernández, ME Sarmiento, JL Leiva, M Martínez, M Fariñas, JF Infante , G Sierra .(CUBA). [email protected]

40

40. EVALUATION OF THE EFFECT OF THE ADMINISTRATION OF HUMAN GAMMAGLOBULINS INA MODEL OF INFECTION WITH BCG IN MICE. A Acosta, N Olivares, A León, Y López, MESarmiento, A Cádiz, A Moya, G Falero, JF Infante, M Martínez , G Sierra . (CUBA)[email protected]

4 41. THE VIABILITY AND THE COLONIZATION CAPACITY OF VACCINAL FORMULATION OFATTENUATED STRAIN 638 (VIBRIO CHOLERAE ). A Talavera, T Moreira, G Año, B Cedré, HDelgado, H García, L García. (CUBA). [email protected]

42

42. ANTIGENICITY AND IMMUNOGENICITY OF INACTIVATED Vibrio cholerae STRAIN. G Año, HGarcía, T Valmaseda, B Cedré, Y Pino, O Ancheta, JL Pérez, L García, A Talavera. (CUBA)[email protected]

43

43. PURIFICATION AND CHARACTERIZATION OF LIPOPOLYSACCHARIDE OF DIFFERENTSEROTYPES FROM PSEUDOMONAS AERUGINOSA. CLINICAL APPLICATIONS. JonatanHernandez, Sara C. Esnard, Aniel Moya, Hilda García, Barbará Cedré, Juan Almenares, AnaCallis, Vismak Torres, Jacqueline Alonso, Armando Cadiz, Gustavo Sierra.(CUBA)[email protected]

44

44. SAFETY AND IMMUNOGENICITY OF A SINGLE DOSE OF LIVE ATTENUATED ORAL CHOLERAVACCINE STRAIN 638, IN ECUADOR. H García, J Menéndez, L Shinkarenko, L E Plaza, LIzquierdo, Barbara Cedré, Tania Valmaseda, Y Pino, J L Pérez, G Año, L García, R Fando, ATalavera, G Sierra (CUBA). [email protected]

45

45. INHIBITION OF ANTICOLONIZING EFFECT OF POSITIVE SERUM FROM HUMANS INOCULATEDWITH THE ATTENUATED STRAIN 638 VIBRIO CHOLERAE O1. JL. Pérez, Y Pino, T Valmaseda,G Año, B Cedré, H García, A Talavera, L García. (CUBA).

46

46. PERSISTENCE OF TETANUS AND DIPHTHERIA ANTITOXIN IN CUBAN PRESCHOOL CHILDREN.Martínez JC, Ochoa RF, Ferriol XR, Estrada EA, Sotolongo FT. (CUBA)[email protected]

47

47. TETANUS AND DIPHTHERIA ANTITOXIN LEVELS IN NEWBORNS FROM HAVANA CITY.Martínez JC, Ochoa RF, Ferriol XR, Estrada EA, Sotolongo FT. (CUBA)[email protected]

48

48. A PRELIMINARY EVALUATION OF THE PROTECTIVE CAPACITY OF A PREPARATION OFIMMUNOGLOBULINS ANTI LYPOPOLISACCHARIDES OF Pseudomonas aeruginosa SEROTYPEO11. J Almenares, S Sifontes, J Cobián, A Moya, A Cádiz, D Díaz, M Camacho. (CUBA)[email protected] and [email protected]

49

49. EXPERIENCE ON THE DEVELOPMENT OF BIOMODELS FOR HAEMOPHILUS INFLUENZAE TYPEB INFECTION. JF Infante, S Sifontes. (CUBA). [email protected]

50

50. BEHAVIOUR OF THE INMUNOLOGICAL PARAMETERS IN PATIENTS WITH PIODERMITIS. L.Sánchez, I. Martén, E. Lay, X. Rodriguez . (CUBA). [email protected]

5 51. EVALUATION OF THE IMMUNE HUMORAL RESPONSE AGAINST B AND C SEROGROUPS OFNEISSERIA MENINGITIDIS IN INFANTS VACCINATED WITH VA-MENGOC-BC. L A. PeláezYañez, E. Estrada, R. Ochoa. (CUBA). [email protected]

52

52. MOUSE MONOCLONAL ANTIBODIES AGAINST OUTER MEMBRANE PROTEINS OF THE CUBANVACCINE STRAIN OF NEISSERIA MENINGITIDIS B:4:P1.19.15. M. E. Pérez, Barbera R., OteroO, Gutiérrez M., Domínguez F, Vidal T, Sierra G, Campa. C. (CUBA). [email protected]

53

53. STUDY OF THE PROTECTIVE CAPABILITY IN MICE OF THE STRAIN SALMONELLA TYPHI TY21ª EXPRESSING THE B SUBUNIT OF CHOLERA TOXIN (CTB). ME Sarmiento, I Feria, LRiverón, A Acosta, M Fariñas, JF Infante, G Sierra. (CUBA). [email protected]

54

54. STUDY OF THE EXPRESSION OF THE B SUBUNIT OF CHOLERA TOXIN IN DIFFERENT LIVEATTENUATED VECTORS. ME Sarmiento, A Acosta , J Díaz , M Martínez, P Estévez , G Sierra.(CUBA). [email protected]

55

55. EXPERIMENTAL MURINE CRYPTOCOCCOSIS. Odalis Asín Milán, Gerardo Martínez Machín,Maria Teresa Ilnaitt, Ileana Valdez. (CUBA). [email protected]

56

56. CHARACTERIZATION OF SHIGELLA FLEXNERI STRAINS: SEROTYPE CORRELATION,ANTIMICROBIAL SUSCEPTIBILITY AND PLASMÍD PROFILE. Roberto Cabrera , MargaritaRamírez , Laura Bravo, Anabel Fernández, Nelsideismy Castañeda. (CUBA). [email protected]

57

57. CARACTERIZATION OF THE IMMUNE RESPONSE OF A VACCINE PREPARATION AGAINSTTHE Haemophilus influenzae TYPE B IN RABBIT SERA. V Vérez, V Fernández, A Rodríguez-Silva, F Cardoso, M Izquierdo, A Mussachio, Y Valdés, MC Rodríguez, L Heynngnezz, J Chang,E Hardy (CUBA). [email protected]

58

58. PRODUCTION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINST THETOXIN CO-REGULATED PILUS OF VIBRIO CHOLERAE. G. Falero, BL. Rodriguez, I. Rodríguez, J.Campos, T. Ledon, E. Valle, Y. Silva, K. Marrero, T. Valmaseda, A. Moreno, R. Fando (CUBA)[email protected]

59

59. GENERAL CHARACTERISTICS OF RECOMBINANT MOREAU BCG STRAIN CARRYING 5CPROTEIN Neisseria meningitidis GENE. I. Griñán; T. Vidal; V. Pasos; C. Campa; G. Sierra, A.Acosta; ME. Sarmiento; JF. Infante. (CUBA)

60

60. RECENT ADVANCES IN THE STUDY OF DCTXPHI, HAP::CELA LIVE CHOLERA VACCINECANDIDATES IN VOLUNTEERS. Rafael Fando, Luis García, Arturo Talavera, Hilda García,Bárbara Cedré, Javier Campos, Boris L. Rodríguez, José L. Pérez, Tania Valmaseda, OliverPérez, Alberto Pérez, Margarita Ramírez, Laura Bravo, Irma González, Talena Ledón, ManuelDíaz Jidy, Miriam Lastre. (CUBA) [email protected]

6 61. CONTRIBUTION TO THE STUDY OF THE INFANT CRIPTOCOCOSIS IN CUBA. Rosaura F.Escobar Aragón. (CUBA). [email protected]

62

62. EXPRESSION OF TCP AND MSHA MAJOR PROTEINS FROM VIBRIO CHOLERAE STRAINS,CULTURE IN DIFFERENT CONDITIONS BY USING SPECIFIC MONOCLONAL ANTIBODIES. Y.Silva, BL. Rodríguez, J. Campos, T. Ledon, K. Marrero, E. Suzarte, E. Martinez, A. Moreno, G.Falero, I. Rodríguez, R. Fando (CUBA). [email protected]

63

63. EVALUATION OF MUCOSAL IMMUNOGENICITY OF 638 ORAL LIVE ATTENUATED EL TORCANDIDATE VACCINE STRAIN. J del Campo et al. (Cuba) [email protected]

64

64. SEARCHING TARGETS FOR ADJUVANT SCREENING. D. Gil et al. (CUBA)[email protected]

65

65. PREVALENCE OF HELICOBACTER PYLORI INFECTION AND CHARACTERISTICS OF STRAINSIN LA HABANA, CUBA. B. Gutiérrez, C. Camou-Juncas, A. Santos, T. Vidal, C. Valmaña, N.González, I. Leonard, R. Martínez, O. Díaz-Canel, M. Paniagua, M.P. Escobar, G. Sierra, G.L.Mendez, Francis Mégraud (CUBA-FRANCE-AUSTRALIA / CUBA-FRANCIA-AUSTRALIA)

IMMUNOLOGY OF BACTERIAL DISEASES II

1. IMMUNOGENICITY OF SALMONELLA TYPHI VI POLYSACCHARIDE VACCINE IN CUBANSCHOOL CHILDREN. Ochoa Azze RF, Martínez Rodríguez JC, Baró Suárez IM, Ginebra IniestaM, Ferriol Marchena XR, Rodríguez Alfonso VM, Sotolongo Padrón FT, Mirabal Sosa M,Armesto del Río M, Leiva Sánchez TA, Menéndez Hernández J, Domínguez HernándezF.(CUBA). [email protected]

2

2. COMPARISON OF THE IMMUNOGENICITY OF SYNTHETIC LINEAR AND MULTIPLE ANTIGENPEPTIDES CONTAINING A PROTECTIVE EPITOPE DERIVED FROM THE MENINGOCOCCALPROTEIN PorA (SUBTYPE 15). S Gonzalez, He Garay, A Cabrales, E Caballero, O Reyes, RPajon. (CUBA). [email protected]

3 3. T-CELL RESPONSE AGAINST THE P64k MENINGOCOCCAL PROTEIN IN BALB/C MICE. SGonzález, C Nazábal, KVS Rao, O Reyes, HE Garay, Sardiñas G, Caballero E, Silva R. (CUBA-INDIA). [email protected]

4 4. SELECTION OF PHAGE-DISPLAYED MIMOTOPE OF NEISSERIA MENINGITIDIS SEROGROUP BCAPSULAR POLYSACCHARIDE. Menéndez T, Cruz Y, Coizeau E, Garay H, Carmenate T,Alvarez A, Guillén G.(CUBA). [email protected]

5 5. HELICOBACTER PYLORI INFECTION IN HAVANA, CUBA . PREVALENCE AND CAGE STATUSOF THE STRAINS. B. Gutiérrez, C. Camou, A. Santos, T. Vidal, C. Valmaña, N. González, I.Leonard, R. Martínez, O. Díaz-Canel, M .Paniagua, M.P. Escobar, G. Sierra. (CUBA).

6 6. IMMUNOGENICITY AND PROTECTION INDUCED BY THE CUBAN TRIVALENT LEPTOSPIRALVACCINE VAX-SPIRALâ IN RISK POPULATIONS. Y. Rodríguez, M. González, A. González, N.Batista, R. Ochoa, X. Ferriol, M. Baró, M. Armesto.(CUBA). [email protected]

7 7. GENERATION OF T CELL LINES AND CLONES FROM A NORMAL DONOR SPECIFIC TOMycobacterium tuberculosis ANTIGENS. Z. Mazorra, G. De Libero. (CUBA-ITALY / CUBA-ITALIA). [email protected]

8

8. STUDY OF SPECIFIC ANTIBODIES RESPONSE IN FRONT OF THE PROTEIN OF 38 KD OFMYCOBACTERIUM TUBERCULOSIS IN HEALTHY INDIVIDUALS VACCINATED WITH BCG.Alina Puig Levy, Herve Bercovier, Yolanta Fishmann, Avi-Chai-Hovav, Yamilé López Hernández,María Elena Sarmiento1, Teresita Vidal Martínez, Rolando Ochoa, Eric Estrada, Gustavo Sierra,Armando Acosta. (CUBA-ISRAEL). [email protected]

9

9. CUTANEOUS LANGERHANS DENDRITIC CELLS AND gd T CELLS IN A MURINE MODEL OFLEPROSY: IN VIVO ANALYSIS. Sandra Bajaña-Miranda, Adriana Flores-Langarica, JuanaCalderon, Monica Heras-Chavarria, Kendy Wek, Jose Angel Vargas, Oscar Rojas-Espinoza,Leopoldo Flores-Romo. (MEXICO). [email protected]

0

10. RISK FACTORS FOR CARRIAGE OF Neisseria meningitidis IN A PRIMARY SCHOOL INHAVANA. Martínez I, López O, Sotolongo F, Zamora L, Bencomo A, Climent J, Mirabal M.(CUBA). [email protected]

11. SPECIFIC IgG ANTIBODIES AGAINST LIPOPOLYSACCHARIDE AND ANTI-ENDOTOXICACTIVITY IN ANTIMENINGOCOCCAL HUMAN IMMUNOGLOBULIN. Balboa JA et al. (Cuba)[email protected]

2

12. ANTIBODY RESPONSES TO MYCOBACTERIUM TUBERCULOSIS AND BCG IN TUBERCULOSISPATIENTS. O Orraca Castillo, A Acosta Domínguez, ME Sarmiento García San Miguel, Y LópezHernández, DY Díaz Domínguez, M Martínez Benítez, N Olivares Arzuaga, A Puig Levi ARodríguez Rojas(Cuba). [email protected]

3

13. THE ANTI NEISSERIA MENINGITIDES B VACCINE OVERCOME THE THYMUS INDEPENDENCEOF POLYSACCHARIDE C IN TODDLER. O Pérez, M Lastre, G Bracho, J del Campo, TRodríguez, C Zayas, C Taboada, G Sierra. (CUBA). [email protected]

4

14. DETECTION OF COMPLEMENT-MEDIATED ANTIBODY-DEPENDENT BACTERICIDAL ACTIVITYIN GROUPS B AND C NEISSERIA MENINGITIDIS COLORIMETRIC SERUM BACTERICIDALASSAY AND ITS VALIDATION. T Rodríguez, M Lastre, B Cedré, J del Campo, E M Fajardo, MHernández, I Delgado, C Zayas, G Sierra, and O Pérez. (CUBA). [email protected]

5

15. ANTIBODIES AGAINTS TYPE I HUMAN IMMUNODEFICIENCE VIRUS (VIH) IN PATIENTS WITHTUBERCULOSIS. Zurita Salinas C, Mestanza Peralta M, Coloma NA, Correa M, Cárdenas P.(ECUADOR) [email protected]

6

16. PHYSICAL-CHEMICAL CHARACTERIZATION BY SDS SOLUBILIZA-TION OF THE OUTERMEMBRANE FROM LEPTOSPIRA POMONA SEROVAR MOZDOK. M Machado Herrera; MNaranjo; M Gonzáles; R Medina; E Abreu; J Abreu; N Batista; V Torres; A Gonzáles; J Oramas.(CUBA) [email protected]

IMMUNOLOGY OF VIRAL DISEASES

7 1. IMMUNE CELLULAR AND HUMORAL RESPONSE IN DIABETES PATIENTS VACCINATED WITHCUBAN ANTI-HEPATITIS B VACCINE. Ariel Jesús Jauma Rojo (Cuba).

8 2. AUTOANTIBODIES DETERMINATION IN PATIENTS WITH MALIGNANT HEMOPATHIES ANDHEPATITIS C. AM Guerreiro et al. (Cuba) [email protected]

9

3. ESTABLISHMENT OF THE ELISA SYSTEM FOR THE DETECTION OF CAPSIDE ANTIGEN FROMHEPATITIS B VIRUS. M. Peña, Y. Lobaina, Z. Nuñez, Y. Pestana, O. Amarantes. (Cuba)[email protected]

20

4. ANALYSIS OF B AND T CELL ACTIVATION IN MESENTERIC LYMPH NODES FROM MICEINFECTED WITH ROTAVIRUS. E Esquivel, L X-Gutierrez, S Lopez, C Arias, F Esquivel.(MEXICO). [email protected]

2 5. EVALUATION OF IMMUNE RESPONSE OF INFECTED DENGUE PATIENTS TO RECOMBINANTNS1 AND E PROTEINS. G Mellado Sánchez , L Santos Argumedo, L Cedillo Barrón. (MEXICO)[email protected]

22

6. DENGUE VIRUS INFECTION INDUCES AN INCREASE IN THE EXPRESSION OF DEATHRECEPTOR TNF-R AND ADHESION MOLECULE ICAM-1 AND SUGGESTS APOPTOSIS OFMICROVASCULAR ENDOTHELIAL CELLS (HMEC-1). S Fonseca-Coronado, L Santos-Argumedo,L Cedillo-Barrón (MEXICO). [email protected]

23

7. GENE EXPRESSION IN HUMAN MACROPHAGES INFECTED WITH DENGUE VIRUS. MMBMoreno-Altamirano, M Romano, M Legorreta-Herrera, FJ Sánchez-García, MJ Colston.(MEXICO). [email protected]

24

8. HIV RNA LEVEL IN CUBAN PATIENTS. A González, A Alvarez, S Palma (CUBA)[email protected]

25

9. NEUROIMMUNE EPIDEMIOLOGICAL VALUE OF REIBERGRAM IN THE FIRST ECHOVIRUS 16MENINGOENCEPHALITIS OUTBREAK IN CUBA. AJ Dorta-Contreras, H Reiber, ME Magraner-Tarrau, B Weissbrick, MT Interián-Morales, E Noris-García, X Escobar-Pérez, T GonzálezHernández (CUBA-GERMANY / CUBA-ALEMANIA)

26

10. VIRAL LOADS AND PHENOTYPIC MARKERS OF HIV PROGRESSION IN CUBAN PATIENTS. AAlvarez, A González, R Molina, C Luzardo, O Calderon. (CUBA). [email protected]

27

11. INFECTIVITY STUDY OF DENGUE VIRUS STRAINS USING IMMUNOFLUORESCENCETECHNIQUE. A Aguilar,N Amin, EM Pérez, G Bolaños, EC Rodríguez, A Talavera. (CUBA)

28

12. SERUM LEVELS OF IL-12, IL-10, RANTES AND NITRIC OXIDE IN DENGUE VIRUS INFECTEDPATIENTS. AB Pérez, G García, T Denny, B Sierra, MV Cabrera, M Alvarez, J Bacallao, MGGuzmán. (CUBA-USA / CUBA-EEUU). [email protected]

29

13. TUMOR NECROSIS FACTOR ALPHA AND NITRIC OXIDE IN BLOOD CELLS SUPERNATANTSSTIMULATED WITH DENGUE VIRUS. AB Perez, G García, B Sierra, M Alvarez, MV Cabrera, LValdés, S Vázquez, MG Guzmán. (CUBA). [email protected]

30

14. ADCC AND DENGUE VIRUS INFECTION: CONTROL OR DAMAGE? G García, MC Arango, ABPérez, L Fonte, B Sierra, R Rodríguez, E Aguirre, MG Guzmán. (CUBA). [email protected]

3

15. A DNA VACCINE OR RECOMBINANT PROTEINS BUT NOT HCV INOCULUMS INDUCED BOTHCELLULAR AND HUMORAL IMMUNE RESPONSES IN MACACA IRUS. A Vina-Rodriguez, SDuenas-Carrera, R Martínez, JC Alvarez-Obregón, J Marante, B Gras, I Gonzalez-Perez, LAlvarez-LajonchEre, G Martinez Donato, EG. Rodríguez, G Guillen Nieto, K Cosme, J MoralesGrillo. (CUBA). [email protected]

32

16. MICE LYMPHOPROLIFERATIVE RESPONSES INDUCED BY A DEN4 TRUNCATEDRECOMBINANT E GLYCOPROTEIN. B Sierra, R Rodríguez, L Lazo, L Hermida, C López, GGarcía, AB Pérez, MG Guzmán. (CUBA). [email protected]

33

17. THE RECOMBINANT DEN 2 ENVELOPE B DOMAIN ELICITS A STRONG SEROTYPE SPECIFICLYMPHOPROLIFERATIVE RESPONSE IN MICE. B Sierra, R Rodríguez, L Lazo, L Hermida, GGuillen, MG Guzmán. (CUBA). [email protected]

34

18. DIALYZABLE LEUKOCYTE EXTRACT (DLE) INHIBITS HIV-1 IN VITRO REPLICATION AS EARLYAS 24 HOURS OF INCUBATION BEFORE VIRUS CHALLENGE IN MT-4 CELLS. Fernández-Ortega C, Ojeda M, Giselle A, Ramos Y, Navea L, Rodríguez L, Casillas D, Lovaina L, Noa E,Ruibal I, M Dubed. (CUBA) [email protected]

35

19. MODIFIED VACCINIA VIRUS ANKARA (MVA) PRIMING AND FOWLPOX VIRUS BOOSTERELICIT STRONGER CTL RESPONSE IN MICE AGAINST AN HIV-1 EPITOPE THAN DNA-POXVIRUS PRIME-BOOST APPROACH. D Vázquez-Blomquist, D Quintana, CA Duarte.(CUBA)[email protected]

36

20. IMMUNIZATION WITH MAPs COUPLED TO CARRIERS: INFLUENCE OF THE EPITOPIC DENSITYAND PRE-EXISTING IMMUNITY TO THE CARRIER. E Iglesias, JC Aguilar, S Martínez, HE Garay,O Reyes. (CUBA). [email protected]

37

21. OZONE THERAPY IN AIDS. A CASE REPORT. N.I. Méndez, S. Menéndez, J. Rivero. (CUBA)[email protected]

38

22. HLA ASSOCIATION IN CUBAN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCYVIRUS TYPE I. STUDY PRELIMINARY. I García, J Suárez, R Alegre, A Alvarez, J Pérez. (CUBA)[email protected]

39

23. IMPROVEMENT OF HCV-SPECIFIC IMMUNE RESPONSES USING A NEW VECTOR OF THEpMAE PLASMID SERIE. J Marante, A Vina-Rodriguez, N Lorenzo, E Brown, EG Rodríguez, SDuenas-Carrera. (CUBA). [email protected]

40

24. INDUCTION OF HUMORAL IMMUNE RESPONSE USING HUMAN INTERFERON ALPHA 2B ANDRECOMBINANT ANTI-HEPATITIS B VACCINE IN ASYMPTOMATIC CARRIER PATIENTS OFHEPATITIS B VIRUS. J A Santiesteban Torres, A González Griego, A Alerm González, J AcostaAcosta, V E. González, E García Castillo, A Montenegro, O Ponce de León (CUBA).

4 25. ADJUVANT CAPACITY OF A LIPOPEPTIDE CONTAINING THE LALF31-52 PEPTIDE ON THEIMMUNE RESPONSE SPECIFIC TO THE HCV CAPSIDE INDUCED BY DNA IMMUNIZATION. JCAlvarez-Obregón, A Alvarez, L Alvarez-Lajoncherè, O Reyes, I Guerra, J Morales, S Dueñas-Carrera. (CUBA) [email protected]

42

26. CHARACTERIZATION AND IMMUNOLOGICAL EVALUATION OF TWO VARIANTS OF THEENVELOPE DENGUE 2 PROTEIN. Laura Lazo, Lisset Hermida, Rayner Rodríguez, Aída Zulueta,Carlos López, Ricardo Silva, Glay Chinea, Jorge Martín, Guadalupe Guzmán, Gerardo Guillén.(CUBA). [email protected]

43

27. RESPONSE OF NEUTRALIZING ANTIBODIES TO SOUTHEAST ASIAN AND AMERICANGENOTYPE OF DENGUE VIRUS TYPE 2. L Bernardo, A Yndart, S Vázquez, L Morier, MGGuzmán.(CUBA). [email protected]

44

28. IMMUNOLOGICAL EVALUATION OF TWO DIFFERENT CONSTRUCTS OF DENGUE-1-P64kCHIMERIC PROTEINS. Lisset Hermida, Rayner Rodríguez, Laura Lazo, Lídice Bernardo, RicardoSilva, Aída Zulueta, Carlos López, Jorge Martín, Iris Valdés, Delfina del Rosario, Glay Chinea,Guadalupe Guzmán, Gerardo Guillén. (CUBA). [email protected]

45

29. IMMUNIZATION WITH HCV SYNTHETIC PEPTIDES CONJUGATED TO CARRIER PROTEINSELICITED STRONG ANTIBODY RESPONSE WITHOUT ADJUVANT IN MICE. L Alvarez-Lajonchere, G Martínez, J Morales, S Dueñas-Carrera. (CUBA). [email protected]

46

30. EVALUATION OF MICE SERA IMMUNIZED WITH SYNTHETIC PEPTIDES OF DENGUE 2 VIRUSUSING ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY ASSAY. MC Montalvo, AB Pérez,G García, S Vázquez, MC Arango, G. Chinea, O Reyes, G Guillén, MG Guzmán. (CUBA)[email protected]

47

31. EVALUATION OF A PANEL WITH ANTIHEPATITIS B POLICLONAL AND MONOCLONALSERUMS FOR SURFACE ANTIGEN EXPRESION DETECTION BY ELISA OF THE HEPATITIS BVIRUS (HBSAG SUBTYPE AYW). M. Peña, Y. Pestana, S. Martinez. (CUBA)[email protected]

48

32. PROCUREMENT OF REFERENCE MATERIALS AGAINST RECOMBINANT HBsAG SURFACEANTIGEN. MC Abrahantes, J Reyes, B Reyes, R Sosa, EM González, M Vega, D Arias, RValdés, E Martínez. (CUBA). [email protected]

49

33. EVALUATION OF AUTOREACTIVITY AFTER IMMUNIZATION OF BALB/C MICE WITH CUBANRECOMBINANT HEPATITIS B VACCINE. M. Romero, B. Sakic, O. Ponce de León. (CUBA-CANADA) [email protected]

50

34. HEPATITIS C VIRAL CORE PROTEIN-EXPRESSING DNA VACCINE INDUCES A STRONG CTLRESPONSE IN MICE. N Acosta-Rivero, S Dueñas-Carrera, L Alvarez-Lajonchere, J Morales.(CUBA). [email protected]

5 35. STUDY OF INFECTION ENHANCEMENT OF DENGUE STRAINS USING A MONOCLONALANTIBODY SPECIFIC TO A RECOMBINANT ENVELOPE PROTEIN FROM DENGUE VIRUS TYPE4. N Amin, M Pupo, R Rodriguez, M Alvarez, H Rodriguez, A Otero, G Guzmán. (CUBA)[email protected]

52

36. IMMUNOGENICITY STUDY OF BEAGLE DOGS FROM CELL CULTURE RABIES VACCINES.Odalys Fidalgo Perera, Ernesto Almora Hernández, Arelys Zamora Fuentes, Georgina PardoGómez, Luis Izquierdo, Maylen Argamasilla Martínez, Niurka Rodríguez Pérez y Gustavo SierraGónzalez. (CUBA). [email protected]

53

37. SURFACE MARKERS OF HEPATITIS B VIRUS INFECTION AND RESPONSE TO VACCINATIONIN A COMMUNITY. Serrano O, Leyva A, Alerm A, González A. (CUBA)[email protected]

54

38. IgG BUT NOT IgM FROM DENGUE 2 IMMUNE HUMAN SERA REACTS WITH DENGUE 4TRUNCATED E GLYCOPROTEIN EXPRESSED IN PICHIA PASTORIS. Rayner Rodríguez, MayraMuné, Susana Vázquez, Gabriel Márquez, Lisset Hermida, Beatriz Sierra, Gerardo Guillén, MaríaG. Guzmán. (CUBA). [email protected]

55

39. IMMUNOLOGIC EVALUATION OF A DTP-HB VACCINE FORMULATION FOR NASALADMINISTRATION. JC Aguilar, R Alemán, Y Lobaina, JC Álvarez, E Iglesias, D García, V Muzio,E Hardy, E Pentón, D Urquiza, N Expósito, G Guillén. (CUBA). [email protected]

56

40. STUDY OF THE ANTIBODIES RESPONSE AGAINST DENGUE VIRAL PROTEIN IN PATIENTSWITH PRIMARY AND SECONDARY INFECTIONS. Sheila Cabezas, Susana Vázquez, MaritzaPupo, Naifi Calzada , Lissette Pérez and María G. Guzmán (CUBA). [email protected]

57

41. INFLUENZA VACCINE: HUMORAL IMMUNITY FOR THE A/JOHANNESBURG/82/96 IN ANELDERLY HOUSE.S Oropesa, A Fanjul, J Muñoz, B Acosta, A Piñón, B Espinosa, MA Oquendo,O Soublet. (CUBA). [email protected]

58

42. KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS (KSHV) SEROPREVALENCE IN CUBANPOPULATIONS. V Kourí, SM Eng, ME Rodríguez, S Resik, O Urraca, PS. Moore, Y Chang, LGonzález (CUBA). [email protected]

59

43. SEROLOGICAL SURVEILLANCE OF MEASLES, RUBELLA AND MUMPS. CUBA 1992-2002. GTorres, R Cancio, M ARibas, I Salazar. (CUBA). [email protected]

60

44. RECOMBINANT HBsAg AGGREGATED "IN VITRO" BY OXIDATIVE STRESS : STUDIES OF ITSANTIGENIC PROPERTIES. Sewer M. , Ramirez W., Tleugabulova D., Fleitas Y., Aguilar J.,Penton E. (CUBA). [email protected]

ADJUVANTS

1. ANALYSIS OF THE CARRIER PROPERTIES OF THE CRY PROTEINS OF Bacillus thuringiensisWHEN ADMINISTERED BY INTRAPERITONEAL AND INTRANASAL ROUTE. G Guerrero, FHernández Terán, L Moreno-Fierros. (MEXICO). [email protected]

2

2. INTRANASAL ADMINISTRATION OF PEPTIDE T1SP10MN(A) CO-ADMINISTERED WITHCHOLERA TOXIN OR CRY1AC, INDUCE CHANGES IN POPULATIONS MUCOSALLYMPHOCYTES B AND T IN BALB/C MICES. R. Esquivel-Pérez, L. Verdín-Terán, L. Moreno-Fierros (MEXICO). [email protected]

3 3. INDUCED IMMUNE RESPONSE FOR THE SIMULTANEOUS ADMINISTRATION OF A DNAVACCINE FOR Brucella abortus AND AN ADJUVANT PLASMID (pGM-CSF). A González, RRivers, E Andrews, A Oñate. (CHILE). [email protected]

4 4. IgA ANTIBODIES AND SISTEMIC T-CELL TOLERANCE BY ORAL IMMUNIZATION WITH ANEntamoeba histolytica PROTEIN FUSED TO CHOLERA TOXIN SUBUNIT B. A Contreras-Rojas, AOlivos, P Ostoa, C Castellanos, JP Laclette, JC Carrero. (MEXICO). [email protected]

5 5. EVIDENCES OF SPECIFIC IMMUNO STIMULATING EFFECT AND LOW TOXICITY OF ANNATURAL ADJUVANT CANDIDATE. Batista A, D Fernández, Urdaneta I, Betancourt J, Pérez O.(CUBA).

6 6. EFFECT OF ACEMANNAN AND CALCIUM SALTS ON THE IMMUNE RESPONSE AGAINSTDIFFERENT ANTIGENS. A Pérez, JC Aguilar, AM Herrera, D Urquiza, V Muzio, E Pentón, MJLeal, GE Guillén.(CUBA). [email protected]

7 7. INFLUENCE OF DIFFERENT ADJUVANTS IN THE IMMUNOLOGICAL RESPONSE AGAINSTDENGUE 2 VIRUS WITH A FUSION PROTEIN. C López, R Rodriguez, L Hermida, L Bernardo, JMartin, I Guerra, L Lazo, A Zulueta, G Guillen, G Guzman. (CUBA). [email protected]

8 8. THE EGF ENCAPSULATION INTO LIPOSOMES MODIFIES ITS IMMUNE RESPONSE IN MICE. MCLuzardo, Y Martínez, L Calderón, Y De León, A De la Barrera, F Pazos, C Alvarez, ME Alonso,ME Lanio (CUBA). [email protected]

9

9. PREPARATION AND EVALUATION OF VI POLYSACCHARIDE-PROTEIN CONJUGATESCOMPOSED OF TETANUS TOXOID OR OMP FROM N. MENINGITIDIS SEROGROUP B AS ACARRIER. M Cuello, O Cabrera, CR Soto, O Pérez, J del Campo, CM Taboada, M Fariñas, GSierra. (CUBA). [email protected]

0

10. DEVELOPMENT OF AN ADJUVATED VACCINE WITH RAPID DELIVERY AGAINST FOOT ANDMOUTH DISEASE VIRUS (FMDV). V. Quattrocchi, N. Fondevila, S. Pappalardo, A. Sadir, P.Zamorano (ARGENTINA). [email protected]

11. CHARACTERIZATION OF P64k AS A CARRIER PROTEIN. S González, R Silva, A Alvarez, GGuillén, E Caballero, A Pérez, Z Cinza A Ruíz, F Dickinson, C Nazábal, G Sardiñas, T Serrano, JSosa, D Guzmán, O Gutiérrez. (CUBA). [email protected]

212. CUBAN ANTI-HEPATITIS B IMMUNOGLOBULIN AS BIOLOGICAL ADJUVANT. V. E. González et

al. (Cuba). [email protected]

3 13. P64K AS A CARRIER PROTEIN OF NEISSERIA MENINGITIDIS PORIN A PEPTIDES. G. Sardiñas,S. Gonzalez, HE Garay, C. Nazábal, O. Reyes, R. Silva. (Cuba). [email protected]

IMMUNODIAGNOSTICS

6

1. OPTIMIZATION OF RECOMBINANT STREPTOLYSIN-O EXPRESSION AND ANALYSIS OF FINALPRODUCT FORMULATIONS SUITABLE FOR IMMUNODIAGNOSIS. B Velázquez, H Massaldi andA Chabalgoity. (URUGUAY). [email protected]

7

2. AUTOANTIBODIES AGAINST EXTRACTABLE NUCLEAR ANTIGENS. A URUGUAYANEXPERIENCE. MI Bethencourt, I Iacobovici. (URUGUAY-SPAIN/URUGUAY-ESPAÑA)[email protected]

8 3. OBTENTION OF HIGH TITRE POLYCLONAL ANTISERA AGAINST PEPTIDIC HAPTENS:MICROCYSTIN LR AND MELITTIN. S Lev. (URUGUAY). [email protected]

9

4. HUMAN TRYPSINOGEN PURIFICATION FROM PANCREATIC TISSUE FOR CYSTIC FIBROSISIMMUNODIAGNOSIS. Antonio Melchor Rodríguez, Liliana Hernández Pérez, Orlando ZuluetaRodríguez, Carlos Martínez Ortiz, Raquel López Cisneros, Carmen Acosta Bas, Nimia FanegoSerrat, Amarilys Frómeta Suárez. (CUBA). [email protected]

20

5. BETA-SUBUNIT HCG PURIFICATION FROM HUMAN CHORIONIC GONADOTROPIN FORIMMUNODIAGNOSIS. Antonio Melchor, Orlando Zulueta, Juliette Cazanave, Liliana Hernández,Carlos Martínez, Ileana Baluja, Dunia Bequec, Celina Machado, Raquel López, Luisa Martínez,Milenen Hernández. (CUBA). [email protected]

2 6. MONOCLONAL ANTIBODY AGAINST FREE BETA-SUBUNIT OF HUMAN CHORIONICGONADOTROPIN. Ileana B. Baluja Conde, Adys I. Brito Moreno, Carmen Acosta Bas, OrlandoZulueta Rodríguez, Antonio Melchor Rodríguez, Isis Amores Sanchéz, Luisa Martínez, MilenenHernández. (CUBA). [email protected]

22

7. TRANSGENIC ANTI COAGULATION FACTOR IX. M. Mahia, A. Dìaz, L. Perez, L.E. Ramos, A.Moya, A. Càdiz, M. Limonta. (CUBA). [email protected]

23

8. IMMUNOLOGICAL CLASSIFICATION OF LYMPHO- AND MYELOPROLIFERATIVE SYNDROMESUSING THE ALKALINE PHOSPHATASE ANTI-ALKALINE PHOSPHATASE (APAAP) METHOD. BBSocarrás, V Marsán, M Sánchez, M Martínez, I Torres, LO del Valle, C Macías, RA Rivero.(CUBA). [email protected]

24

9. MONOCLONAL ANTIBODY AGAINST HUMAN TRYPSIN: PRODUCTION, CHARACTERIZATION,AND USE FOR DIAGNOSIS. Carmen Acosta Bas, Ileana B. Baluja Conde, Adys I. Brito Moreno,Maya Rosa Rodríguez López, Antonio Melchor, Liliana Hernández, Amarilys Frómeta, María E.Selles, Luisa Martínez. (CUBA). [email protected]

25

10. ENDOTHELIAL ADHESION MOLECULES ICAM-1, VCAM-1 AND E-SELECTIN IN PATIENTSWITH ACUTE CORONARY SYNDROME. Consuelo Macías , Rinaldo Villaescusa , Lázaro delValle , Victor Boffil, Girelda Cordero, Alberto Hernández, Porfirio Hernández , José ManuelBallester. (CUBA). [email protected]

26

11. EVALUATION OF THE NEUTROPHILS RESPONSE USING THE REDUCTION OF THE NITRO BLUEOF TETRAZOLIUM(NBT) AND THE OPSONOPHAGOCYTIC INDEX TECHNIQUES. Edisley ZailaLago, Yudania Reyes Cepero, Cándido León Márquez, Ernesto Caraballosa Yero. (CUBA)[email protected]

27

12. ENZYME-LINKED IMMUNOSORBENT ASSAY FOR 17a-HYDROXYPROGESTERONE (17OHP) INSERUM AND DRIED BLOOD SPOTS ON FILTER PAPER. E González, N Marrero, A Frómeta, MMónaga, D Herrera, E Castells, P Pérez, A Baloy, J Hernández. (CUBA). [email protected]

28

13. VALIDATION OF A NESTED PCR ASSAY UMELOSA HCV FOR DETECTION OF HEPATITIS CVIRUS. I. Gonzalez-Perez, Y. J. González, A. Armas, A. Vina-Rodriguez, A. Medina, N. Trujillo,M.T. Pérez, R.L. Solís. (CUBA). [email protected]

29

14. EXPERIENCE OF THE IMMUNOASSAY CENTER IN THE PRODUCTION OF POLYCLONALANTIBODIES FOR IMMUNODIAGNOSIS. L. Martínez; J.R. Vivar; V. Soto; A. Lorenzo; M.Montes de Oca; A. Melchor; O. Zulueta; P. Pérez; I. Valdivia; R. Cápiro; M.L. Hernández; R. DelSol. (CUBA). [email protected]

30

15. LATEX TEST FOR SERUM MYOGLOBIN IN THE DIAGNOSIS OF ACUTE MYOCARDIALINFARCTION. MC Pico, IG Giraldino, M Alvarez, P Pedroso, H Carol. (CUBA)[email protected]

3 16. CHIMERIC SYNTHETIC PEPTIDES CONTAINING TWO IMMUNODOMINANT EPITOPES FROMTHE GAG P19 PROTEIN AND THE ENVELOPE GP46 GLYCOPROTEIN FOR THEIMMUNODIAGNOSIS OF HTLV-II VIRUS INFECTION. M Hernández, Y Márquez, L Pozo, C Silva,Ch Rodríguez, D Higginson. (CUBA). [email protected]

32

17. ANTIGENIC MIXTURE OF SYNTHETIC PEPTIDES FOR THE IMMUNODIAGNOSTIC OF HTLV-I/II.Y. Márquez, M. Hernández, R.A. Vázquez, L. Pozo, C Silva. (CUBA). [email protected]

33

18. CELLULAR IMMUNOPHENOTYPING IN THE DIAGNOSIS OF CHRONIC LYMPHOID LEUKEMIAS.M Sánchez, V Marsán, B Socarrás, RA Rivero, M Martínez, P Hernández, C Macías, LO delValle. (CUBA). [email protected]

34

19. DETECTION OF HLA-DR15 AND HLA-DQ6 BY PCR-SSP TECHNIQUE AND ITS USE IN THEDIAGNOSIS OF NARCOLEPSY. Raul Ferreira, Flora Calzadilla, Adriana Artiles, Lizette Bonet,Pedro Figueredo. (CUBA).

35

20. THE USEFULNESS OF UMELOSA HCV CUALITATIVO KIT AS SUPPLEMENTAL TEST FORCONFIRMATION OF HCV INFECTION. I. Gonzalez-Perez, Y. J. González, A. Vina-Rodriguez, A.Armas, R.L. Solís. (CUBA) [email protected]

36

21. VALIDATION OF AN ELISA FOR THE QUANTITATION OF MONOCLONAL ANTIBODIESAGAINST THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEIN 24. N Ruiz , MIzquierdo, E Silva, D Martín, MT Pérez. (CUBA). [email protected]

3722. CUBAN ANTI-HEPATITIS B IMMUNOGLOBULIN WITH DIAGNOSTIC AIMS IN VIVO. E. García et

al. (CUBA) [email protected]

38

23. IMMUNODIAGNOSTIC TEST FOR ANTIBODIES RESPONSE DETECTION AGAINST TICKINFECTION IN BOVINE SERUM SAMPLES. E Torres, C Talavera, R Blanco, N Abad, H Machado,G Gómez. (CUBA) [email protected]

IMMUNOTECHNOLOGY

4 1. DENDRITIC CELL IMMUNIZATION IMPROVES PRODUCTION OF MONOCLONAL ANTIBODIESAGAINST THE REGULATOR OF MHC CLASS II EXPRESSION (CIITA). P Vargas, C Cortés, LVargas, M Rosemblatt, MR Bono. (CHILE). [email protected]

42

2. OBTAINING VIRAL IMMUNOGENS BY MEANS OF THE FILAMENTOUS PHAGE DISPLAY.PRELIMINARY RESULTS. Ela María Pérez, Frank Camacho, Osmany Larralde, Félix Daphnis,Odalys Fidalgo, Raiza Martínez, Alicia Aguilar, Nevis Amin, Miriela Capo, Gustavo Sierra.(CUBA). [email protected]

43

3. A SENSITIVE COMPETITION ELISA WITH IMMOBILIZED ANTIGEN FOR QUANTIFINGSTICHOLYSINS I AND II, TWO CYTOLYSINS FROM THE SEA ANEMONE Stichodactylahelianthus. A Otero, A Hidalgo, MC Pico. (CUBA). [email protected] PDF

44

4. PEROXIDASE-LABELED STICHOLYSINS METHOD FOR LOCALIZATION OF STICHOLYSINS INTHE SEA ANEMONE STICHODACTYLA HELIANTHUS. MC Pico, Y Noa, V Pérez, M Izquierdo, OGuerra, JF Infante, A Otero. (CUBA). [email protected]

45

5. NEUTRALIZATION OF HEMOLYTIC ACTIVITY OF STICHOLYSIN II, A CYTOLYSIN FROM THESEA ANEMONE Stichodactyla helianthus. MC Pico, A Basulto, I Casadelvalle, A.J. Otero.(CUBA). [email protected]

46

6. POLYCLONAL ANTIBODIES TO SHPI-1, A POLYVALENT PROTEASE INHIBITOR FROM THESEA ANEMONE STICHODACTYLA HELIANTHUS. I Casadelvalle, MC Pico, V Marañón, EFacenda, C Gilvá. (CUBA). [email protected]

47

7. VALIDATION OF COLORIMETRIC VIBRIOCIDAL ASSAY FOR DETERMINE SERUM ANTIBODIESTO Vibrio cholerae. Bárbara Cedré, Yutssandry Viel, Tamara Rodríguez, Gemma Año, IrmaGonzález, Ileana Delgado, Hilda García, Yadira Pino, Tania Valmaseda, Arturo Talavera, LuisGarcía. (CUBA). [email protected]

48

8. VALIDATION OF ELISA FOR DETERMINE ANTIBODIES ANTI-LPS IN HUMAN SERUMINOCULATED BY ORAL ROUTE WITH 638 V. CHOLERAE STRAIN EL TOR OGAWA. YadiraPino Navarro, Tania Valmaseda Pérez, Yudisey Medina Sánchez, Bárbara Cedré Marrero,Gemma Año López, Hilda M. García Sánchez, José Luis Pérez Quiñoy, Arturo Talavera Coronel,Irma González Novo, Ileana Delgado Arrieta y Luis García Imia (CUBA). [email protected]

49

9. IMMUNOPURIFICATION OF THE HEPATITIS B SURFACE ANTIGEN USING A PLANT-DERIVEDHBsAg-SPECIFIC ANTIBODY. Rodolfo Valdés, Biunayki Reyes, Tatiana Alvarez, Janet García,Waldo Ortiz, José A. Montero, Raudel Sosa, Leonardo Gómez, Sigifredo Padilla, YurisleydisAldama , Alejandro Figueroa, Lamay Dorta, Damián Fernández, Deborah Geada and José Brito(CUBA). [email protected]

50

10. INFLUENCE OF THE EXTRACTION BUFFER ON MONOCLONAL ANTIBODY QUANTITY ANDINTEGRITY FROM TOBACCO PLANTS. Rodolfo Valdés, William Ferro,Sigifredo Padilla,Leonardo Gómez, Raudel Sosa, Roberto Pérez, Otto Mendoza,Merardo Pujol, Jose Enrique Brito.(CUBA). [email protected]

5 11. OBTENTION OF CHICKEN ANTIBODIES THAT RECOGNIZE NUCLEOSIDE ANALOGS USED INNON RADIOACTIVE DNA DETECTION. Dannelys Perez Bello, Judith Miranda, Mirta ZayasAcosta, Chryslaine Rodriguez Tanty, David Higginson Clarke, Ana María Riverón Rojas, EstebanGutiérrez Calzado, Rüdiger Schade. (CUBA-GERMANY / CUBA-ALEMANIA).

52

12. MOUSE MONOCLONAL ANTIBODIES AGAINST ABO BLOOD GROUP ANTIGENS IN CUBA: ITSEVALUATION IN THE 4TH INTERNATIONAL WORKSHOP. Rivero RA, Bencomo AA, Alfonso Y,Suárez LE, Díaz M. (CUBA). [email protected].

53

13. HUMAN HAEMOCLASSIFICATION BY USE OF SPECIFIC YOLK ANTIBODIES OBTAINED AFTERIMMUNISATION OF CHICKENS AGAINST HUMAN BLOOD GROUP ANTIGENS. RM García, EJGutiérrez, E Schade. (CUBA-GERMANY / CUBA-ALEMANIA). [email protected]

54

14. COMPARISON OF THREE METHODS FOR NONRADIOACTIVE IN VIVO DNA LABELING INEscherichia coli Dannelys Pérez Bello, Viana Manrique Suárez, Celso Pérez Bolaños, JudithMiranda López, Gabriel Pérez Pérez, Lilia López Canovas, David Higginson Clark, ChryslaineRodríguez Tanty, Ana Maria Riverón Rojas. (CUBA).

55

15. RIBULOSE 1,5 DIPHOSPHATE; GENERATION OF MONOCLONAL ANTIBODIES FORIMMUNOAFFINITY CHROMATOGRAPHY AND PROTEIN QUANTIFICATION. Déborah Geada,Rodolfo Valdés, Marcos González, Dioslaida Urquiza, Leonardo Gómez, Abdel Hidalgo, DulceMaría Ares. (CUBA). [email protected]

56

16. CLONING, EXPRESSION AND PURIFICATION OF HUMAN CD6 EXTRACELLULAR DOMAIN INE. COLI USED TO DETECTION HIORT1 MAB. E Santana, A Aguirre, L Ayra, G Márquez, JSánchez, Y Carpio, FO Castro. (CUBA). [email protected]

57

17. PRODUCTION OF MONOCLONAL ANTIBODIES BY THE ASCITES METHOD: ACOMPREHENSIVE ANALYSIS OF THE SCALE TO REDUCE ANIMAL SUFERING. O. Mendoza, R.Valdés, R. Alemán, M. González, B. Reyes, S. Padilla,T. Alvarez, A. Tamayo, D. Fuentes, R.González, O. Hernández, J. Arronte. (CUBA). [email protected]

58

18. IDENTITY TEST OF THE OMV PROTEIN FROM CUBA VACCINE VA-MENGOC-BC® USINGMONOCLONAL ANTIBODIES. M. E. Pérez, Barbera R., Otero O., Domínguez F., Sotolongo F.Sierra G, Campa C. (CUBA). [email protected]

59

19. IMMUNOBLOT VERSUS ELISA FOR THE PRIMARY SCREENING IN THE DEVELOPMENT OFMOUSE MONOCLONAL ANTIBODIES AGAINST OUTER MEMBRANE PROTEINS OF Neisseriameningitidis B:4:P1.(7B).4. M. E. Pérez, Otero O., Barbera R., Gutiérrez M., Domínguez F.,Sotolongo F. Sierra G, Campa C. (CUBA). [email protected]

60

20. GENE THERAPY USING NAKED PLASMID DNA ENCODING VEGF121 IN ANIMAL MODELS OFISCHEMIC DISEASES. AG Ojalvo, A Seralena, NS Vispo, R Silva, R Vázquez, Y Puchades, A Alí,P Lopez-Saura, JF Montequín, LT Sorell, A Aldama, MA Alfonso, Rafael Simón, Armando Seuc,N González, L Guevara, N Chaos, O Creach, R González, JF Batista, Y Peña, M Coca, A Perera,T García-Osuna, H Domínguez, JL Reyes, L Herrera. (CUBA). [email protected]

6

21. KINETIC OF EXPRESSION OF THE PLANTIBODY-HB01 SPECIFIC FOR THE SURFACE ANTIGENOF HEPATITIS B VIRUS IN Nicotiana tabacum (CUBA) Leonardo Gómez Bayolo, Merardo Pujol,Rodolfo Valdés, William Ferro, Roberto Pérez, Sigifredo Padilla, José Brito, Carlos Borroto,Alberto Núñez, Milagro Font, René Gallo, Julio César Sánchez. (CUBA)[email protected]

62

22. PROCCESSING OF FRESH TRANSGENIC TOBACCO PLANTS FOR PURIFICATION OF A HBsAg-SPECIFIC ANTIBODY. Rodolfo Valdés, Leonardo Gómez, Sigifredo Padilla, Merardo Pujol,Vladimir Leal, Orlando Herrera, Tatiana Alvarez, Otto Mendoza, Jorge Luis Vega, José Brito,Carlos Borroto. (CUBA). [email protected]

63

23. DIRECT IDENTIFICATION OF TUMOR ANTIGENS BY AUTOLOGOUS ANTIBODY SCREENING. OGires, M Muenz, M Schaffrik, C Kieu, B Mack, W Hammerschmidt, R Zeidler. (GERMANY)[email protected]

TUMOR IMMUNOLOGY AND IMMUNOTHERAPY

1. ADVANCES IN THE DETERMINATION OF TUMOR MARKERS IN COLORECTAL CARCINOMA. MV Croce, AG Colussi, G Ramacciotti, A Segal-Eiras (ARGENTINA). [email protected]

2 2. PATTERNS OF MUC1 TISSUE EXPRESSION DEFINED BY AN ANTI MUC1 CYTOPLASMIC TAILMONOCLONAL ANTIBODY IN BREAST CANCER. MV Croce, M Isla-Larrain, C Rua, M Rabassa,A Segal-Eiras. (ARGENTINA). [email protected]

3 3. EXPRESSION OF CARBOHYDRATE AND PEPTIDIC ANTIGENS IN BREAST CANCER. MV Croce,M Isla-Larrain, C Rua, A Segal-Eiras. (ARGENTINA). [email protected]

4

4. INTRATUMORAL AND REGIONAL LYMPH NODES CYTOKINES GENE EXPRESSION IN BREASTCANCER PATIENTS. L Llanes-Fernández, MC Arango-Prado, JM Alcocer-González, V Madrid-Marina, S Franco-Odio, R Camacho-Rodríguez, AM González-Sánchez, R Tamez-Guerra, CRodríguez-Padilla. (CUBA-MEXICO)

5 5. WALKER 256 TUMOR MHC CLASS I EXPRESSION DURING THE SHIFT FROM "A" VARIANTINTO THE IMMUNOGENIC "AR" VARIANT. AS Schanoski, PB Juliano, CBL Campos, TCSCavalcanti, AN Viera-Matos, O Rettori, F Guimarães. (BRASIL/BRAZIL). [email protected]

6 6. THE ANTI-TUMORAL ACTIVITY OF VEGETAL SPECIES FOUND IN AMAZONIC REGION. FRFNascimento, BTF Silva, JO Viana, GB Cruz, K Arruda, N Gadelha, RNM Guerra.(BRASIL/BRAZIL). [email protected]

7 7. POSSIBLE PARTICIPATION OF THE COMPLEMENT SYSTEM IN THE DEVELOPMENT OFAUTOIMMUNE MANIFESTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA. R Villaescusa, etal. (Cuba). [email protected]

8 8. TREATMENT OF LEUKEMIC CELLS (HL60) WITH DIMETHYLAMIDE-CROTONIN TRIGGERSAPOPTOSIS DEPENDENT OF CASPASES -2 AND -9, BUT NOT CASPASE -6 ACTIVATION. MCAnazetti, PS Melo, N Durán, M Haun. (BRAZIL/BRASIL). [email protected]

9 9. REGULATION OF Bcl-2 EXPRESSION IN LEUKEMIC CELLS (HL60) BY VIOLACEIN AS AMECHANISM OF APOPTOSIS INDUCTION. N Bromberg, PS Melo, C Bincoletto, GZ Justo, MHaun, N Durán (BRAZIL/BRASIL). [email protected].

0 10. ANTITUMORAL ACTIVITY OF DEHYDROCROTONIN. PS Melo, GZ Justo, N Durán, M Haun.(BRAZIL/BRASIL). [email protected]

11. POLYAMINES AS BIOMARKERS OF NEOPLASTIC GROWTH IN MICE WITH L5178YLYMPHOMA TREATED WITH Bursera fagaroides. R Reynoso, A Santerre, J I Delgado, CSandoval, A Puebla.(MEXICO). [email protected]

2

12. RED BLOOD CELLS OSMOTIC FRAGILITY ALTERATIONS INDUCED BY TOTAL AND PLASMAFRACTIONS FROM RATS BEARING PROGRESSIVE AND REGRESSIVE VARIANTS OF WALKER256 TUMOR. TC Cavalcanti, CC Gregorini, F Guimarães, O Rettori, AN Vieira-Matos(BRAZIL/BRASIL). [email protected]

3

13. EFFECTOR, MEMORY AND NAIVE PHENOTYPES IN CYTOTOXIC T LYMPHOCYTES FROMLUNG ADENOCARCINOMA PATIENTS. H Prado-García, D Aguilar Cázares, H Flores-Vergara, HMorales-Fuentes, F Ávila-Moreno, JS López-González. (MEXICO). [email protected].

4

14. PULMONARY CARCINOMAS INDUCE ALTERATIONS IN DIFFERENTIATION, MATURATIONAND FUNCTION OF HUMAN DENDRITIC CELLS. F Ávila-Moreno, S J López-González, H Prado-García, C Sánchez-Torres. (MEXICO). [email protected]

5

15. MODULATION OF THE CELLULAR IMMUNE RESPONSE AND CYTOKINES PRODUCTION BY INVITRO PERILLYL ALCOHOL ON T CELLS FROM TUMOR-BEARING MICE. E Flores, S del Toro, Adel Toro, T García, MG Ramírez, A Daneri. (MEXICO). E-mail: [email protected]

6

16. NKG2D AND 2B4 EXPRESSION ON NK CELLS FROM PATIENTS WITH CERVICALCARCINOMA. S del Toro, A del Toro, T García, J Peregrina, E Flores, MG Ramírez, A Daneri.(MEXICO). [email protected]

7

17. EXPRESSION OF ZETA CHAIN IN T LYMPHOCYTES AND NK CELLS FROM PATIENTS WITHUTERINE CERVICAL CARCINOMA. T García, A del Toro, J Peregrina, E Sánchez, P Sánchez, Sdel Toro, A Daneri. (MEXICO). [email protected]

8

18. CD44-HYALURONIC ACID INTERACTION MODULATES METALLOPROTEINASES IN A T CELLMURINE LYMPHOMA AND IN INFLAMMATORY LEUKOCYTES. L Alaniz, P Cabrera, SGreczanik, G Blanco, E Alvarez, SE Hajos. (ARGENTINA). [email protected]

20

19. IMMUNOTHERAPY OF ADVANCED BREAST CANCER WITH AN HETEROPHILIC GANGLIOSIDE(NEUGCGM3) CANCER VACCINE. A Carr, E Rodríguez, MC Arango, R Camacho, M Osorio, GCarrillo, Z Valdés, Y Bebelagua, M Gabri, R Pérez, LE Fernández. (CUBA-ARGENTINA)[email protected]

2 20. EPIDERMAL GROWTH FACTOR RECEPTOR-BASED ACTIVE IMMUNOTHERAPY OF CANCER.Anabel de la Barrera. (CUBA). [email protected]

22

21. EXPRESSION OF LYMPHOCYTE SURFACE ANTIGENS IN BREAST CANCER PATIENTS. AGonzález, E Noris, A Torrella, M C Arango, T Badía, M E Faxas. (CUBA)[email protected]

23

22. A MONOCLONAL ANTIBODY AGAINST NeuGc-CONTAINING GANGLIOSIDES CONTAINS AREGULATORY IDIOTOPE INVOLVED IN THE INTERACTION WITH B AND T CELLS. A Perez, ESMier, N Santiago Vispo, AM Vazquez, R Perez. (CUBA). [email protected]

24

23. A CHIMERIC ANTI-N-GLYCOLYL-GANGLIOSIDE ANTIBODY: IMMUNODOMINANCE OF ITSVARIABLE REGION. A Lopez, C Mateo de Acosta, J Lombardero, K Sosa, R Perez, AMVazquez. (CUBA). [email protected]

25

24. IMMUNE RESPONSES IN BREAST CANCER PATIENTS IMMUNIZED WITH AN ANTI-IDIOTYPICANTIBODY MIMICKING NeuGc-CONTAINING GANGLIOSIDES. A Díaz, M Alfonso, R Alonso, GSaurez, M Troche, M Catalá, RM Díaz, R Pérez, AM Vázquez. (CUBA). [email protected]

26

25. A TGFa CANCER VACCINE. Ayllete Mulet, Greta Garrido, Anabel Alvarez, Tamara Menéndez,Rolando Pérez, Luis Enrique Fernández. (CUBA). [email protected]

27

26. EVALUATION OF THE HUMORAL IMMUNE RESPONSE TO NEUGCGM3/ VSSP VACCINE INMETASTATIC MELANOMA PATIENTS. A. Torrella, E. Noris, A. González, M.C. Arango, B.Rodríguez, M. Osorio, L. Anasagasti, E. Rodriguez, R. Mon, A. Carr, L.E. Fernández (CUBA)[email protected].

28

27. INDUCTION OF IMMUNE RECOGNITION TO AUTOLOGOUS EGFR. B Sánchez. A de la Barrera,E Suárez, R Pérez, A Ullrich, LE Fernández.(CUBA). [email protected]

29

28. CD6+ CELLS IN BENIGN BREAST LESIONS AND CANCER DEVELOPMENT M E Faxas García, IPérez B, M E Guerra Y. (CUBA). [email protected]

30

29. RISK FACTORS AND IMMUNOLOGICAL PARAMETERS IN CERVICAL CANCER. G. León, MEFaxas, B. Rodríguez, O. Bosques Diego, R. Ruiz Lorente. (CUBA). [email protected]

3 30. CHARACTERIZATION OF IMMUNOGENICITY AGAINST TWO GROWTH FACTORS (EGF ANDTGF ALPHA) USING RECOMBINANT FUSION PROTEINS BETWEEN THESE MOLECULES ANDP64K PROTEIN FROM NEISSERIA MENINGITIDIS AS A NEW CANCER VACCINE APPROACH. GGarrido, A Mulet, A Álvarez, T Menéndez, L.E Fernández. (CUBA). [email protected]

32

31. LHRH BASED VACCINE DECREASE THE VOLUME OF PROSTATE IN ADULT MALE RATS. FFuentes, L Calzada, J Junco, R Basulto, E Bover, E Pimentel, Y López, H Hernández. (CUBA)[email protected]

33

32. PERIPHERAL T CELL REGULATION AGAINST SELF-ANTIGENS IN AUTOIMMUNITY ANDCANCER. E. Montero, G. Nussbaum, J. Kaye, R. Perez, A. Lage, I. Cohen.(CUBA-ISRAEL)[email protected]

34

33. LEUKOCYTE AND RECOMBINANT INTERFERON IN THE TREATMENT OF MYCOSIS FUNGOIDE.LONG-TERM SURVIVAL. A del Río, S Collazo, B Sagaró, B Gutiérrez, M Cortina, C Ochoa, CValenzuela, P López-Saura. (CUBA). [email protected]

35

34. T CELL AND GANGLIOSIDES BASED VACCINES: ARE THEY INVOLVED? C. Mesa, Z. Mazorra,L.E.Fernández (CUBA) [email protected]

36

35. EVALUATION OF THE HUMORAL IMMUNE RESPONSE TO NEUGCGM3/ VSSP VACCINE INADVANCED BREAST CANCER PATIENTS. E. Noris, A. Torrella, A. González, MC. Arango, B.Rodríguez, M. Osorio, L. Anasagasti, E. Rodriguez, R. Mon, A. Carr, L.E. Fernández. (CUBA)[email protected]

37

36. IMMUNOGLOBULIN DISTURBANCES IN PATIENTS WITH HODGKIN´S DISEASE. A Arce, RVillaescusa, JC Merlín, AM Guerreiro, LM Morera, C Ustariz, P Hernández. (Cuba)[email protected]

ANTIGEN PRESENTATION/TRANSPLANTATION

46

1. THE DECREASE ON T CELL COUNTS AFTER A SINGLE DOSE OF IMMUNOSUPPRESSIVEDRUGS IN RENAL TRANSPLANT PATIENTS CAN BE ASCRIBED TO A LOW DOSE OFPREDNISONE. D Sauma, R Mora, A Fierro, J Morales, C Herzog, M Rosemblatt, MR Bono.(CHILE). [email protected]

47

2. REPRESENTATION OF CLASS I AND II ANTIGENS IN RECEIVERS OF KIDNEY GRAFTS. M CClares, M. Domínguez. (CUBA). [email protected]

48

3. HLA EXTENDED HAPLOTYPES IN A SAMPLE OF THE CUBAN CONTEMPORARY POPULATION.R Alegre, I Garcia, J Suárez, J Beltrán, J Martínez-Laso, E Gómez-Casado, A Arnaiz-Villena.(CUBA-SPAIN / CUBA-ESPAÑA). [email protected]

49

4. GENETIC AND PHENOTYPICAL FREQUENCY STUDY OF HLA ANTIGENS INOPHTHALMOLOGICAL DISEASES: VOGNT - KOYANAGI - HARADA AND PRIMARY OPENANGLE GLAUCOMA. LM Morera et al. (CUBA) [email protected]

OTHER TOPICS I

55

1. ALTERATIONS OF THE COMPLEMENT SYSTEM IN PATIENTS WITH DIABETIC NEPHROPATHY.JC Merlín et al. (CUBA). [email protected]

56

2. INTRODUCTION OF IMMUNOLOGY TEACHING TO THE STUDY PLAN FOR THE PHARMACYCAREER AND ITS IMPORTANCE FOR THE PROFESSIONAL PERFORMANCE OF GRADUATES.Beatriz Tamargo Santos et al. (CUBA) [email protected]

57

3. ZINC SUPPLEMENTS AND IMMUNE SYSTEM CELLS FUNCTIONS IN DIABETICS. Mahia VM etal. (CUBA). [email protected]

58

4. ACTION OF THE INJECTABLE EXTRACTS OF ALOE BARBADENSIS ON THE APPEARANCE OFINFECTIOUS COMPLICATIONS AND THE LEVELS DE INMUNOGLOBULINS. M RodríguezAcosta, E Castellano Port, T Vazquéz González, A Sin Mayor, M Larionova, N Johnston Dreke,RA Moya. (CUBA) [email protected]

59

5. EFFECT OF THE RFC2A ABOUT THE CELLULAR VIABILITY DE HUMAN NEUTROPHILS. A SinMayor, M Larionova, Map ecechea Coffigny, N Johnston Dreke. (CUBA)[email protected]

60

6. EFFECT OF THE INJECTABLE EXTRACT OF ALOE BARBADENSIS ON THE LYMPHOBLASTICTRANSFORMATION OF THE BURNT PATIENT. T Vazquéz González, M Rodríguez Acosta, ECastellano Port, A Sin, M Larionova, N Johnston Dreke, RA Moya. (CUBA)[email protected]

6 7. ANTIVIRAL EFFECT OF TWO TINTURES OBTAINED OF HYPERICUM CULTIVATED IN CUBA. ECastellanos Puerto, JL Pérez de Alejo, Ml Machin Lugones. (CUBA). [email protected]

IMMUNOLOGY OF PARASITE DISEASES

1. ROLE OF IL-4 IN EXPERIMENTAL INFECTION BY THE HELMINTH Echinococcus granulosus. GFerragut, S Dematteis, A Baz. (URUGUAY). [email protected]

2

2. THE ATHYMIC LEW-Whn10rnu "NUDE RAT" AS A MODEL TO STUDY T-CELL INDEPENDENTMECHANISMS OF RESISTANCE AGAINST T. gondii. JC Sepulveda-Arias, MC Kempf, DWedekind, HJ Hedrich, MF Cesbron-Delauw, U Gross, T Herrmann. (COLOMBIA-GERMANY-FRANCE/COLOMBIA-ALEMANIA-FRANCIA). [email protected]

3 3. T CELL UNRESPONSIVENESS IN RATS CONGENITALLY INFECTED WITH THE PARASITEToxoplasma gondii. JC Sepulveda-Arias, T Herrmann. (COLOMBIA-GERMANY/COLOMBIA-ALEMANIA). [email protected]

4 4. STUDIES ABOUT IMMUNE RESPONSE IN RATS INFECTED WITH Toxoplasma gondii VIA MILK.JC Sepulveda-Arias, J Nussbaumer, T Herrmann. (COLOMBIA-GERMANY/COLOMBIA-ALEMANIA). [email protected]

5 5. DIFFERENTIAL PHAGOCYTIC CAPACITY OF Nramp1 GENE CONGENIC MACROPHAGE LINESTO THE INFECTION WITH CONIDIAS OF Paracoccidioides brasiliensis. M del P Jiménez, ARestrepo, LE Cano, LF García. (COLOMBIA). [email protected]

6

6. CELL EXPRESSION OF COSTIMULATORY MOLECULES NO DIFFERS IN PATIENTS WITHLOCALIZED CUTANEOUS LEISHMANIASIS AND ENDEMICALLY EXPOSED ASYMPTOMATICS.CM Trujillo, M Zuluaga, PJ Patiño, ID Vélez, SM Robledo. (COLOMBIA)[email protected]

7 7. EXPRESSION OF PEPTIDE-HLA COMPLEXES IN INFECTED MACROPHAGES WITH Leishmaniabrasiliensis. S Télles, F Puerta, S Santaella. (VENEZUELA). [email protected]

8 8. MODULATION OF THE COMPLEMENT SYSTEM BY Trypanosoma cruzi CALRETICULIN. VFerreira, S Tzima, A Gringas, MC Molina,C Valck, A Rojas, W Schwaeble, A Ferreira. (CHILE-UK/CHILE-REINO UNIDO). [email protected]

9 9. IMMUNOPATHOGENESIS OF GLOMERULONEPHRITIS IN VISCERAL LEISHMANIASIS (VL)INVOLVES CD4+ T CELLS, IMMUNOGLOBULIN AND MODULATION OF APOPTOSIS. H Goto,FAL Costa, R Mathias, MG Prianti, A Sesso, J L Guerra. (BRAZIL/BRASIL). [email protected]

0

10. AMEBIC CYSTEINE PROTEINASE 2 (EhCP2) PLAYS EITHER A MINOR OR NO ROLE IN TISSUEDAMAGE IN ACUTE EXPERIMENTAL AMEBIC LIVER ABSCESS IN HAMSTERS. A Olivos-García,A González, R López, MC García de León, E Tello, M Nequiz, I Montfort, R Pérez-Tamayo.(MEXICO). [email protected]

11. EVALUATION OF THE ROLE OF CELL-MEDIATED IMMUNITY IN DERMATOPHYTOSIS . ARKhosravi, M Franco, M Mahmoudi. (IRAN-BRAZIL/IRAN-BRASIL). [email protected]

2

12. APOPTOSIS AND CYTOKINE PROFILE IN THE EVOLUTION OF EXPERIMENTAL VISCERALLEISHMANIASIS. JAL Lindoso, FA Pettito, FA Freitas, H Goto. (BRAZIL/BRASIL)[email protected]

3 13. MALARIA IN THE SUB SAHARAN AFRICA. KO Agyapong, GK Nyarko, AM Koomson.(GHANA). [email protected]

4

14. SPECIFIC TRANSFER FACTOR PROTECTS MICE AGAINST LETHAL TOXOPLASMOSIS. A.Rodríguez, I. Vila, A. Moya, J. Hernández, L. Solarana, A. Cadiz, M. Limonta, J. O. Rodríguez,A. Fachado (CUBA). [email protected]

5

15. CONSTRUCTION AND EVALUATION OF IMMUNOGENICITY AND INDUCED PROTECTION INBALB/C MICE IMMUNIZED WITH A GENOMIC LIBRARY OF EXPRESSION OF TRYPANOSOMACRUZI. A Ruiz Espinosa, E Alberti Amador, AM Montalvo Alvarez, R García Miniet, MB.Martínez Benitez, ME Sarmiento García San Miguel, A Acosta Domínguez (CUBA).

6

16. SIGNIFICANT PROTECTIVE EFFECTS OF NAKED DNA BASED IMMUNIZATION FROM LETHALTOXOPLASMOSIS IN MICE. A. Rodríguez, A. Fachado, I. Vila, J. L. Gonzalez, A. Acosta, M. E.Sarmiento. (CUBA). [email protected]

7 17. CELLULAR INMUNITY ALTERATIONS IN PATIENTS WITH RECURRENT GIARDYASIS. B Ferrer,G Reiter, M. C Clares. (CUBA). [email protected]

8

18. IMMUNOMODULADOR EFFECT OF THE VIMANG AND MANGIFERINA IN THE THE IMMUNEHUMORAL RESPONSE TO THE SPORES OF A MICROSPORIDIAN PARASITE . Dagmar GarcíaRivera, René Delgado Hernández, Florencio Martínez Ubeira, José M. Leiro Vidal. (CUBA-SPAIN/ CUBA-ESPAÑA). [email protected]

9

19. EVALUATION OF AUTORREACTIVITY IN BALB/C MICE IMMUNIZED WITH NUCLEIC ACIDSFROM Trypanosoma cruzi. Aniran Ruiz Espinosa, Esteban A. Amador, Martha Rodriguez Peña,Arturo Münster, O. Ponce de León, María E. Sarmiento García San Miguel, Armando AcostaDomínguez, Gustavo Sierra (CUBA). [email protected]

20

20. INTESTINAL AMEBIASIS. IMMUNOLOGICAL AND BIOMOLECULAR DEMONSTRATION OF THEOVERESTIMATION OF A HEALTH PROBLEM. Luis Fonte Galindo, María de los A. FernándezFerrer, Lizet Sanchez Valdés, Humberto Marín Iglesias, Ivón Montano Goodridge. (CUBA)[email protected]

2 21. IgA ANTIBODIES AND SISTEMIC T-CELL TOLERANCE BY ORAL IMMUNIZATION WITH ANEntamoeba histolytica PROTEIN FUSED TO CHOLERA TOXIN SUBUNIT B. A Contreras-Rojas, AOlivos, P Ostoa, C Castellanos, JP Laclette, JC Carrero. (MEXICO) [email protected]

22

22. HUMORAL AND CELULAR ESPECIFIC RESPONSE IN BALB/C MICE IMMUNIZED WHITH AGENOMIC EXPRESSION LIBRARY OF TRYPANOSOMA CRUZI. Mignelys Padilla Rivas et al.(Cuba).

23

23. INDUCTION OF PROTECTION AND SYSTEMIC AND MUCOSAL ANTIBODY RESPONSES INMICE IMMUNIZED INTRANASALLY WITH Naegleria fowleri EXTRACT TOGETHER WITHCry1Ac AS AN ADJUVANT. S Rojas, M Rodríguez, R Campos, R López, L Moreno. (MEXICO)[email protected]

IMMUNODEFICIENCIES

26

1. A B CELL IMMUNODEFICIENCY IN AN EIGHT-MONTH CHILD WITH BCG VACCINATION. GLópez, A Garibay, A Esparza, G Galindo, L Flores, R Hernández, B Alvarez, M Pérez, S Estrada, IEstrada, L Santos. (MEXICO). [email protected]

27

2. HEMIN: IN VITRO EFFECT ON HUMAN LYMPHOCYTES FROM HEALTHY BLOOD DONORS. LOdel Valle, V Marsán, M Sánchez, I Torres, BB Socarrás, M Martínez, C Macías, RA Rivero, PHernández, JM Ballester. (CUBA). [email protected]

28

3. JALEA REAL: AN EFFECTIVE ALTERNATIVE FOR THE TREATMENT OF PATIENTS WITHCELLULAR INMUNODEFICIENCY. O. de la Guardia, J. Espinosa, T Planos, M. Savigne, L.Nogueira, Z Lemus. (CUBA).

29

4. USE OF INTRAVENOUS GAMMAGLOBULIN IN PRIMARY IMMUNODEFICIENCY. A. Noda, B.Rodríguez, A.Vidal. (CUBA). E mail [email protected]

SIGNAL TRANSDUCTION / CELL INTERACTIONS

34

1. MOLECULAR APPROACHES TO THE STUDY OF THE PROTEIN OF 67 KDa (p67phox) OF THENADPH OXIDASE SYSTEM OF PHAGOCYTIC CELLS. AA Arias, MC Dinauer, J Ding, MTRugeles, PJ Patiño. (COLOMBIA-USA/COLOMBIA-EEUU). [email protected]

35

2. T-KININOGEN INHIBITS CON A-STIMULATED MAPK ACTIVITY IN LYMPHOCYTES ANDMACROPHAGES. C Acuña-Castillo, M Aravena, E Leiva-Salcedo, V Pérez, C Gómez, SNishimura, R Walter, F Sierra. (CHILE-USA/CHILE-EEUU). [email protected]

36

3. PREFERENTIAL DEVELOPMENT OF CD4+CD25+ SUPPRESSOR T CELLS WITH DISTINCT TCRCHARACTERISTICS IN MICE EXPRESSING A SINGLE PEPTIDE-MHC CLASS II COMPLEX. MAGavin, JD Fontenot, E Negrou, Y Zhu, I Wilson, R Strong, AY Rudensky. (USA/EEUU)[email protected], [email protected]

37

4. MECANISMS OF DOWN-REGULATION OF MHC CLASS II (MHC-II) BY IMMUNE COMPLEXES(IC) ON HUMAN MONOCYTES. P Barrionuevo, M Beigier-Bompadre, GC Fernández, S Gómez,MS Palermo, MA Isturiz. (ARGENTINA). [email protected]

38

5. GENE EXPRESSION IN CELLS TRANSFECTED WITH DIFFERENT ISOFORMS OF CIITA. CCortés, D Munroe, L Gangi, M Rosemblatt, MR Bono. (CHILE-USA/CHILE-EEUU)[email protected]

39

6. No inhibition of the citotoxicity activity on human natural killer cells by anti alpha 4 chainmonoclonal antibodies. C. Macías , del Valle L.O., Ballester J.M. (CUBA). [email protected]

40

7. EFFECT OF IFN-g ON THE EXPRESSION OF SMAD-7 IN HEPATIC STELLATE CELLS "HSC". IYañez-Sanchez, P Alatorre-Carranza, M Bueno-Topete, V Delgado-Rizo. (MEXICO)[email protected]

IMMUNOLOGY OF ALLERGIC DISEASES

46

1. IgE AND MAST CELLS CO-SEGREGATION IN ORAL TOLERANCE GENETICALLY SELECTEDSTRAINS OF MICE. AC Silva, RC Ribeiro, MS Levy, MFS Silva, O Sant'Anna. (BRAZIL/BRASIL)[email protected]

47

2. ALLERGENIC POLLENS AND POLLINOSIS IN SANTANDER CITY, SPAIN. V de Benito, C Sainz,J Soto. (SPAIN/ESPAÑA). [email protected]

48

3. IgE REACTIVITY TO RECOMBINANT ALLERGENS FROM Blomia tropicalis IN CUBAN ALLERGICPATIENTS. L Puerta, A Labrada, L Caraballo. (COLOMBIA-CUBA). [email protected]

49

4. A COMPARATIVE EVALUATION OF SERUM EOSINOPHIL CATIONIC PROTEIN (S-ECP) ANDTOTAL BLOOD IgE AS DIAGNOSTIC PARAMETERS IN PEDIATRIC ASTHMA. TG Naidu, JQueiroz, ALC Bessa. (BRAZIL/BRASIL) [email protected]

50

5. ETIOPATHOGENIC ROLE OF FUME OF FISH'S FLOUR FACTORIES IN THE DEVELOPMENT OFALERGIC MANIFESTATIONS BY CHILDREN AT THE PROVINCE OF CHANCAY, LIMA, PERU. JLAguilar Olano, R Capcha Mendoza, P Rojas, A Ramos, P Hurtado T., E Sanchez, I Goyzueta.(PERU). [email protected]

5 6. BIOLOGICAL ACTIVITY OF ISOLATED MAJOR ALLERGENS OF Dermatophagoides siboney. BNavarro, E Facenda, A Más, A Labrada, RL Castro, Y Oliva, M Febles. (CUBA)[email protected]

52

7. STABILITY OF IGE BINDING ACTIVITY OF DOMESTIC MITE ALLERGENS. A Labrada, EFacenda, N Lorenzo, A Más, R Quintero. (CUBA). [email protected]

53

8. CONTAMINATION WITH MITE ALLERGENS IN THE DOMESTIC ENVIRONMENT OF ALLERGICCHILDREN. L Infante, A Labrada, E Facenda, RL Castro, B. Fernández , B Luis (CUBA)[email protected]

54

9. ISOLATION AND CHARACTERIZATION OF A LOW MOLECULAR WEIGHT ALLERGENFRACTION OF Blomia tropicalis. A Labrada, M Labrada, K Uyema, B Navarro, M Febles, LPuerta (CUBA-COLOMBIA). [email protected]

55

10. CHARACTERIZATION OF rBlo t 13, RECOMBINANT ALLERGEN FROM Blomia tropicalis USINGMONOCLONAL ANTIBODIES. M Labrada, K Uyema, M Sewer, A Labrada, M González, LPuerta, L Caraballo. (CUBA-COLOMBIA). [email protected]

56

11. LIPOSOME ENCAPSULATION OF THE MAJOR ALLERGENS OF Dermatophagoides siboney FORSPECIFIC IMMUNOTHERAPY. L. Calderón, E. Facenda, Y. Martínez, A. Otero, M.C. Pico, A.Labrada, M.E. Lanio. (CUBA). [email protected]

57

12. NUCLEIC ACIDS ENCODING A HOUSE DUST MITE ALLERGEN FROM Dermatophagoidessiboney. O. Jorge, R.J. Romero, B. Fernández, B. Luis, D. Torralba, B.González (2) and A.Labrada. (CUBA). [email protected]

58

13. DIAGNOSTIC EFFICACY OF THE SKIN PRICK-TEST, USING ALLERGEN EXTRACTS OFCOMMON DOMESTIC MITES, IN CUBAN CHILDREN. RL Castro, R Andina, A Labrada, D Fabré,Y Oliva, M González. (CUBA). [email protected]

59

14. DIAGNOSTIC EFFICACY OF THE SKIN PRICK-TEST, USING ALLERGEN EXTRACTS OFCOMMON DOMESTIC MITES IN A CUBAN ADULT POPULATION. RL Castro, A Labrada, AAbdo, R Espino, M Ronquillo, M González, RE Aranda. (CUBA). [email protected]

60

15. DEVELOPMENT OF ELISA BASED ON SPECIFIC POLYCLONAL ANTIBODIES, FORQUANTIFYING THE GROUP 1 MAJOR ALLERGEN OF HOUSE DUST MITES. K Uyema, MMontesino, A Labrada, M Febles. (CUBA). [email protected]

6 16. NEW APPROACH FOR in vitro DIAGNOSIS OF THE SPECIFIC IgE RESPONSE TO CYNODONDACTYLON POLLEN. L. Díaz, A. Montenegro, A Gonzales, A Dacourt, M Romero, O Ponce deLeón, O Glez, R Rodríguez. (CUBA). [email protected]

62

17. BRONCHIAL ASTHMA. -TREATMENT WITH INTACGLOBÍN (INTRAVENOUSGAMMAGLOBULIN). A. Noda, A.Vidal, B. Rodríguez. (CUBA). E mail [email protected]

VETERINARY IMMUNOLOGY

1. IMMUNE RESPONSE OF THE EQUINE INFECTIOUS ANEMIA DISEASE VIRAL GP 45 PROTEINTO A SYNTHETIC PEPTIDE IN MICE. A Soutullo, MI García, A Racca, A Baillat G Capello, JCPerin, G Tonarelli, I Malan Borel.(ARGENTINA). [email protected]

2

2. DEVELOPMENT AND EVALUATION OF AN ENZYME-LINKED INMUNOSORBENT ASSAY FORQUANTIFICATION OF THE HUMORAL RESPONSE OF CATTLE VACCINATED AGAINSTCampylobacter fetus. MV Repiso, MA Baraibar, MA Olivera, S Silveyra, J Battistoni(URUGUAY). [email protected]

3 3. APOPTOSIS IN LUNGS OF PIGS INTRATRACHEALLY INOCULATED WITH Mycoplasmahyopneumoniae. ST Cruz ST, G García-Tovar, J Luna, S Martínez R, L Flores, R Mena.(MEXICO). [email protected]

4 4. LYSOSOMAL DEGRANULATION IN POLYMORPHONUCLEAR NEUTROPHILS: A NOVELMECHANISM OF SURVIVAL OF PATHOGENIC b-HEMOLYTIC Staphylococcus aureus IN THEBOVINE MAMMARY GLAND. TG Naidu. (BRAZIL/BRASIL). [email protected]

5 5. IMMUNOCHEMICAL CHARACTERIZATION OF PORINS FROM SALMONELLA SEROVARS OFIMPORTANCE IN POULTRY. A Estrada Garcia, B Ortiz Lopez, VF Ortiz Navarrete. (MEXICO).alioshaeg@yahoocom.

6 6. COMPARISON OF DIFFERENT ROUTES IN THE Brucella abortus DNA VACCINATION. EAndrews, A Cabrera, A González, R Rivers, H Folch, A Oñate.(CHILE). [email protected]

7 7. CLONING AND CHARACTERIZATION OF THE CHICKEN YOLK SAC IGY RECEPTOR. AP WestJr, PJ Bjorkman. (USA/EEUU). [email protected]

8 8. INTRASPLEEN IMMUNIZATION OF BALB/C MICE WITH A DNA VECTOR FOR BRUCELLAABORTUS. C A Muñoz; E Andrews, S Cespedes, G Donoso, A Oñate. (CHILE)[email protected]

9 9. DETECTION AND COUNTING OF MAST CELLS IN PIG'S LUNG INFECTED EXPERIMENTALLYWITH MYCOPLASMA HYOPNEUMONIAE. ST Cruz , SS Martínez Robles, LJ Tórtora, FGGarrido, LM Vega, RL Flores. (MEXICO). [email protected]

0

10. LACK OF SPECIFIC HUMORAL IMMUNE RESPONSE, IN A CALF LATENTLY INFECTED WITHBOVINE HERPES VIRUS 1.1. AN EPIDEMIOLOGICAL RISK. P Alonzo, U Benavides, F Isnardi, RPuentes, H Carol, J Bonnevaux, N Fondevila, SA Romera, AM Sadir, J Maisonnave.(URUGUAY-ARGENTINA). [email protected]

11. EVALUATION OF A NEW MARKER BHV-1 VACCINE TO INDUCE PROTECTION AGAINSTVIRUS INFECTION IN CATTLE WHEN ADMINISTERED SUBCUTANEOUSLY. SA Romera, MPuntel, MP Del Médico Zajac, P Zamorano, P Maliandi, N Mattion, AM Sadir (ARGENTINA)[email protected]

2

12. EVALUATION OF PROTECTION CONFERRED BY INACTIVATED BHV-1 OR BHV-5 VACCINESAGAINST BHV-5 INFECTION. MP Del Médico Zajac, SA Romera, M Puntel, P Zamorano, MAlegre, P Maliandi, N Mattion, AM Sadir A.M. (ARGENTINA). [email protected]

3 13. DNA VECTORS FOR Brucella abortus. R Rivers, A González, E Andrews, A Oñate. (CHILE)[email protected]

4

14. IgG IN SERUM, TISSUE AND PLACENTAL EXTRACTS AT DIFFERENT TIMES DURING SWINEPREGNANCY. M Koncurat, O Riesco, A Garro, G Yaful, D Williamson, D Lacolla. (ARGENTINA)[email protected]

5

15. INDUCTION OF CD8+ T CELLS IN THE INFECTION CAUSED BY Brucella abortus. R LópezSantiago, J Ríos Garcés, A López Merino, G Schurig, MC Moreno Lafont. (MEXICO)[email protected]

6 16. HUMORAL IMMUNE RESPONSE IN ALPACAS INFECTED EXPERIMENTALLY WITH FASCIOLAHEPATICA. O S Timoteo, V Neyra, G Leguia, JR Espinoza (PERU). [email protected]

7

17. NRAMP1 EXPRESSION CORRELATES WITH HIGH LEVELS OF iNOS AND MHC INGRANULOMAS OF M. bovis infected cattle. A.L. Pereira, C. Estrada-Chavez, C. Arriaga, M.Hernádez, R. Mancilla. (MEXICO). [email protected]

818. COMPARATIVE STUDY OF THE IMMUNE RESPONSE OF FIVE DIFFERENT SPECIES OF TILAPIA

(Oreochromis). J. Casas, A. Santerre, R. León, G. Zaitseva. (MEXICO). [email protected]

9 19. STUDY THE EFECT OF LEAD IN VIVO IN THE IMMUNE RESPONSE OF RED TILAPIA(Oreochromis mossambicus). R Solis, G Zaitseva (MEXICO). [email protected]

20

20. HUMORAL IMMUNE RESPONSE TO BOOPHILUS MICROPLUS BM95 ANTIGEN IN MICE,FOLLOWING A DNA PRIME-PROTEIN BOOST IMMUNIZATION STRATEGY. Gianna Izquierdo,Omar Farnós, Diana M. González, Marisdania Joglar, Elsa Rodríguez, Ricardo Lleonart. (CUBA)[email protected]

2 21. IMMUNODETECTION OF COLONIZING ANTIGENS IN ENTEROTOXIGENIC ESCHERICHIA COLICELLS ISOLATED FROM PIGLETS WITH DIARRHOEA IN CUBA. M D Castro, A Campal, NArteaga, A Miranda, J Junco, L León, S Casas, T Alvarez, F Fuentes. (CUBA)[email protected]

22

22. EVALUATION OF A MONOCLONAL ANTIBODIES PANEL DIRECTED AGAINST FIMBRIALANTIGENS K88, K99, F41 AND 987P OF ENTEROTOXIGENIC ESCHERICHIA COLI. J Junco, ACampal, A Miranda, M Castro, N Arteaga, S Casas , L León, T Alvarez, D Sanchez, GFernández, G Fontirroche. (CUBA). [email protected]

23

23. EVALUATION OF A COMPETITIVE ELISA IN THE IMMUNE RESPONSE OF THE RABBITHAEMORRHAGIC DISEASE VIRUS. O. Valdés, M. García, L. Izquierdo (CUBA)[email protected]

24

24. REPONSE TO MITOGENS BY PERIPHERAL PORCINE LYMPHOCYTES IN THE PERI-IMPLANTATIONAL PERIOD. C. Greco, F. Cuello and Vivas, A. (ARGENTINA)[email protected]

25

25. ADDITIONAL VALUE OF THE CONSERVATION OF THE CUBAN CREOLE DONKEY FORPRODUCTION OF HIPERIMMUNE SERA. Eduardo Sánchez Blanco, Hiram Fong Rodríguez,Román Sánchez Pompa, Gustavo Sierra González, Francisco Velásquez Rodríguez. (Cuba)[email protected]

CYTOKINES / INFLAMMATION

26

1. A SYNTHETIC PEPTIDE HOMOLOGOUS TO THE FUNCTIONAL DOMAIN OF HUMANINTERLEUKIN 10 DOWNREGULATES THE EXPRESSION OF THE MHC CLASS I ALPHA CHAINAND TAP 1/2 IN HUMAN MELANOMA CELLS. M Kurte et al. (CHILE). [email protected]

27

2. INTER-INDIVIDUAL VARIATIONS ON CONSTITUTIVE IL-10 mRNA AND PROTEIN LEVELS ANDITS ASSOCIATION WITH GENETIC POLYMORPHISMS. A Suárez, P Castro, R Alonso, L Mozo,C Gutiérrez. (SPAIN/ESPAÑA). [email protected]

28

3. A RAPID PROCEDURE FOR DISRUPTION OF WHITE BLOOD CELLS IN PRODUCTION OFTRANSFER FACTOR. C Noyola, D Castillo. (MEXICO). [email protected]

29

4. SELECTED MICE FOR ORAL TOLERANCE RESISTANCE: POSITIVE CORRELATION TOINFLAMMATORY RESPONSE. MFS Silva, CS Bianchi, AC Silva, TC Barja-Fidalgo, F Cunha, ANóbrega. (BRAZIL/BRASIL). [email protected]

30

5. MURINE PERITONEAL MACROPHAGE ACTIVATION BY Orbignya phalerata (BABASSU)TREATMENT. FRF Nascimento, AP Azevedo, ESB Barroqueiro, RNM Guerra, M Russo.(BRAZIL/BRASIL). [email protected]

3 6. ADHESION OF B CELL LINES TO TONSIL ENDOTHELIAL CELLS INDUCES MHC CLASS IIMOLECULES. L Vargas, L Reyes, M Rosemblatt, MR Bono. (CHILE) [email protected]

32

7. ASSOCIATED INTERLEUKIN-1 COMPOSITE GENOTYPE IN MEXICAN ALZHEIMER PATIENTS. MMéndez, R Valdés, G Silva, J Villalba (MEXICO) [email protected],[email protected]

33

8. MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II (MHC) POLYMORPHISMS IN PATIENTSWITH IDIOPATHIC PULMONARY FIBROSIS (IPF). R Falfán, A Camarena, G Pérez, V Muñoz, ACamacho, A Juárez, M Selman. (MEXICO). [email protected]

34

9. IN VITRO AND IN VIVO IFNg REGULATION OF CHEMOKINE RECEPTORS IN PERIPHERALBLOOD LEUKOCYTES FROM PATIENTS WITH ATOPIC AND INFLAMMATORY DISEASES.REGULATORY ROLE OF IFN g IN ATOPIC AND INFLAMMATORY DISEASES. Iraldo Bello Rivero,Cimara Bermudez, Madelyn Rodríguez, Elizabeth Blanco, Yanelda García, Yudith Rodríguez,Carmen Valenzuela, Pedro López Saura. (CUBA). [email protected]

34

10. STRESS-INDUCED DELETERIOUS INFLAMMATORY EVENTS OF THE HAIR FOLLICLE CAN BECOUNTERACTED BY A TOPICALLY ACTIVE HAIR GROWTH STIMULATOR. AC Zenclussen,EMJ Peters, E Hagen, BF. Klapp, R Paus, PC Arck. (ALEMANIA-ARGENTINA/GERMANY-ARGENTINA). [email protected]

36

11. LOW BUT NOT HIGH DOSES OF ANTI-TNF-A OR ANTI-IFN-G ARE PROTECTIVE IN A MURINEMODEL OF SEPTIC SHOCK. R Márquez, G Ramírez, A Díaz, J Paniagua, R Bojalil. (MEXICO)[email protected]

37

12. ARSENIC DELAYS IL-2 SYNTHESIS AND DOWNREGULATES CD4 AND CD8 EXPRESSION INHUMAN T LYMPHOCYTES STIMULATED WITH PHA. G Galicia, R Leyva, E Tenorio, POstrosky, R Saavedra. (MEXICO). [email protected]

38

13. T CD3+ LYMPHOCYTES AT THE DIFFERENT INTESTINAL COMPARTMENTS SHOW DISTINCTINTRACELLULAR CYTOKINES PROFILES. A Reséndiz-Albor , M Méndez- Rodríguez, R Valdés, RLópez-Revilla, L Moreno-Fierros. (MEXICO). [email protected]

39

14. DECREASE OF T LYMPHOCYTES PROLIFERATIVE RESPONSE AND CYTOKINES LEVELS BYTRYPSIN. PE Sánchez-Hernández, A del Toro-Arreola, S del Toro-Arreola, A Daneri-Navarro.(MEXICO). [email protected]

40

15. IL-10 INDUCES DISRUPTION OF LIPID RAFTS MOBILIZATION IN MURINE BONE MARROW-DERIVED DENDRITIC CELLS. G Acosta-Pérez, ME Castro-Mussot, R Tascón, B Stockinger, MJColston, FJ Sánchez-García. (MEXICO-UK/MEXICO-REINO UNIDO). [email protected]

4

16. EFFECT OF AN EXTRACT OF Uncaria tomentosa (UÑA DE GATO) ON THE PRODUCTION OFTHE TUMORAL NECROSIS FACTOR - ALPHA IN A MODEL IN VIVO AND ITS ACTION LIKE ANANTI-INFLAMMATORY AGENT IN VITRO. P A Rojas, O S Timoteo, R Capcha, A Marcelo, APlaza, R Bauer, I Merfort, J L Aguilar. (PERU-GERMANY/PERU-ALEMANIA)[email protected]

42

17. TOLL-LIKE RECEPTORS (TLRs) EXPRESSION IN HUMAN MIXED BLOOD MONONUCLEARCELLS FROM PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) ANDCYTOKINE SERUM PROFILE. N Ramírez-Cruz C Maldonado, M Cuevas-Urióstegui, I Secundino,J Castañón, C López, I Estrada, A Isibasi. (MEXICO) E-mail: [email protected]

43

18. THE -308 TUMOR NECROSIS FACTOR PROMOTER POLYMORPHISM IN SEVERE SEPSIS. J.Guerrero, G. Echevarría, F. Nickel, C. Rodas, A. Cruzat, J. Contreras, A. Dotte, J. Castro, J.C.Aguillón. (CHILE). Email: [email protected]

44

19. PRO-INFLAMMATORY INTERLEUKINS IN TWO HEALTHY POPULATIONS EXPOSED TODIFERENT LEVELS OF AIR POLLUTING AGENTS. A.C. González-Villegas, M.L. Pita-López, V.Davydova, E. Moreno-Ramírez, G. Zaitseva. (MEXICO). [email protected]

45

20. DIALYZABLE LEUKOCYTE EXTRACT (DLE) MODULATES CCR5 AND MIP-1a IN MT-4 cells.Ojeda M, Chávez L, Rodríguez L, Casillas D, Ramos , C Fernández-Ortega. (CUBA)[email protected]

46

21. ELEVATED cAMP LEVELS COULD MEDIATE THE DIFFERENTIAL EFFECTS OF DIALYZABLELEUKOCYTE EXTRACT (TRANSFER FACTOR) ON INFLAMMATORY EVENTS IN LEUKOCYTES.M Ojeda Ojeda, C van 't Veer, C Fernandez-Ortega, M Araña, WA Buurman. (CUBA-THENETHERLANDS / CUBA-HOLANDA). [email protected]

47

22. EFFECT OF THE PROTEIN AND VITAMIN A DEFICIENCY IN THE DIET ON THE GENEEXPRESSION OF THE INTERLEUKIN 1 (IL-1). de las Cagigas A., Ferreira R., Sanchez V.,Mengheri E. (CUBA-ITALY / CUBA-ITALIA).

48

23. IFNa 2b INDUCES APOPTOSIS AND PROTEASOME-MEDIATED DEGRADATION OF P27KIP1 INA HUMAN LUNG CANCER CELL LINE. A Moro, SE Perea, C Pantoja, A Santos, MJ Araña, MSerrano. (CUBA). [email protected] PDF

4924. IL-15 REGULATES HPV E7 IN A CERVICAL CANCER CELL LINE. A. Santos, R. Cruz, Y. Morera,

A. Moro, S. Perea. (CUBA). [email protected]

50

25. EXPRESSION OF IL-13rh/Ckm FUSED PROTEIN IN THE MURINE MYELOMA CELL LINE J558LAC Campal, A Santos, A de la Hera (CUBA-SPAIN / CUBA-ESPAÑA)[email protected]

526. IL-1alpha AMPLIFIES THE PROLIFERATION OF TF-1 CELLS CULTIVATED IN THE PRESENCE OF

IL-13rh/Ckm. NEW STRATEGY TO DETERMINE THE BIOLOGICAL ACTIVITY OF THE IL-1aINTERLEUKINE. AC Campal, A de la Hera. (CUBA-SPAIN / CUBA-ESPAÑA)[email protected]

52

27. ESTABLISHMENT OF THE LIMITS OF ACCEPTANCE OF THE FINAL PURIFIED PRODUCT OFTHE PRODUCTION PROCESS OF THE RECOMBINANT HUMAN INTERLEUKIN-2. IsabelApezteguía, Adriana M. Perera, Danny Perez, Haydée Gerónimo, Galina Moya, NiurmysMartínez, Maribel Vega, Raudel Sosa, Fidel H. Breña (CUBA). [email protected]

53

28. THE INFLUENCE OF SOME DEGRADATION PATHWAYS ON THE BIOLOGICAL ACTIVITY OFIFN ALPHA 2B, INTERLEUKIN 2 AND EPIDERMAL GROWTH FACTOR. Ll Ruiz, M Zurita, NReyes, L Duany, H Gerónimo, K Aroche, E Hardy. (CUBA). [email protected]

54

29. DEVELOPMENT OF LIQUID AND FREEZE-DRIED FORMULATIONS OF INTERFERON ALPHA 2B.Ll Ruiz, N Reyes, J Sotolongo, L Duany, J Ferrero, K Aroche, E Hardy. (CUBA)[email protected]

55

30. NEW FORMULATIONS OF INTERLEUKIN-2 RETAINING THE BIOLOGICAL ACTIVITY OF THECYTOKINE. N Reyes, Ll Ruiz, K Aroche, J Sotolongo, K Soto, H Gerónimo, E Hardy. (CUBA)[email protected]

56

31. EVALUATION OF THE CYTOKINES PATTERN IN AN ANIMAL MODEL OF RHEUMATOIDARTHRITIS. MC Domínguez, D García del Barco, C Taylor, D Urquiza, D Rodríguez, J Suárez, AVázquez, N Merino, K Cosme, G Padrón. (CUBA). [email protected]

57

32. EFFECTS OF LBP-DERIVED PEPTIDES ON TNF-ALPHA PRODUCTION IN AN EXPERIMENTALMODEL OF ENDOTOXIC SHOCK. AM Rodríguez, I Rodríguez-Alonso, I Hernández, MJ Araña.(CUBA). [email protected]

58

33. EFFECT OF ANTI-LPS PEPTIDES IN THE EXPRESSION OF GAMMA INTERFERON IN A MURINEMODEL OF INFECTION WITH Salmonella typhimurium. I Hernández Ramirez, I Rodríguez-Alonso, M Araña Rosaínz. (CUBA). [email protected] PDF

59

34. ADMINISTRATION OF LBP-DERIVED PEPTIDES IN TWO DIFFERENT ANIMAL MODELS OFSEPSIS. I Rodríguez-Alonso, AM Rodríguez, I Hernandez, MJ ArañA. (CUBA)[email protected]

60

35. KAWASAKI DISEASE (KD). TREATMENT WITH INTRAVENOUS GAMMAGLOBULIN. A. Noda,A.Vidal, B. Rodríguez. (CUBA). [email protected]

6 36. CIRCULATING LEVELS OF PRO-INFLAMMATORY CYTOKINES AND OTHER MARKERS OFINFLAMMATION IN SEVERELY BURNED CHILDREN. F. Iglesias, N. Salazar, M. Colás, A.Magdariaga, M.J. Araña (CUBA). [email protected]

62

37. THE PROTEIN BPI (bactericidal/permeability-increasing) IMPROVES THE SURVIVAL INNEONATAL EXPERIMENTAL SEPSIS BY Escherichia coli. Javier Mancilla-Ramírez, Pilar García-Roca, J. Jesús Gaitán-Meza, Norma del Carmen Galindo-Sevilla, Francisco Javier Larios-Medina.(MEXICO). [email protected]

63

38. INCREASE OF THE SOLUBLE RECEPTORS OF IL-1 AND TNFa IN SEPTIC NEONATES TREATEDWITH GM-CSF AND INTRAVENOUS IMMUNOGLOBULIN (IVIG). Javier Mancilla-Ramírez, IrmaElia Arce-García, Jacqueline Lara-Sánchez, Federico Javier Ortiz-Ibarra, Norma del CarmenGalindo-Sevilla. (MÉXICO). [email protected]

64

39. CANDIDATE VACCINE STRAINS OF VIBRIO CHOLERAE INDUCE A DIFFERENTIAL ANDSPECIFIC ARRAY OF THREE PROINFLAMMATORY CYTOKINES IN INTESTINAL EPITHELIALCELL LINE. BL. Rodríguez, A. Rojas, J. Campos, T. Ledon, E. Valle, K. Marrero, R. Fando.(Cuba). [email protected] PDF

65

40. THE EXPRESSION OF CO-STIMULATORY MOLECULES AND CYTOKINES SECRETION DEPENDIN PART OF PROLACTIN. Chávez-Rueda K et al. (MEXICO). [email protected]

OTHER TOPICS II

1. DIFFERENCES BETWEEN THE LARGE AND SMALL INTESTINE ON THE PHENOTYPE OFLAMINA PROPRIA LYMPHOCYTES. A Reséndiz-Albor, M Méndez- Rodríguez, R López-Revilla, LMoreno-Fierros. (MEXICO). [email protected]

2. EVALUATION OF IMMUNOTOXICITY OF CHRONIC INTOXICATION WITH SODIUM ARSENITEIN Balb/c MICE. C Escudero-Lourdes, CE Medina de la Garza, R Quezada-Calvillo. (MEXICO)[email protected]

3. IgG CONTAINING CELLS IN INTRAEPITHELIAL AND LAMINA PROPIA INTESTINALCOMPARTMENTS ARE INCREASED BY INTRAPERITONEAL IMMUNIZATION WITH Cry1Ac. LVerdín Terán, RM Esquivel Pérez, L Moreno Fierros. (MEXICO). [email protected]

4. THE IMMUNOSUPPRESSIVE EFFECT OF LUPEOL AND ITS DERIVATIVES ON ANTIBODY ANDCELLULAR MEDIATED IMMUNE RESPONSES. RNM Guerra, AM Mendes, LMS Silveira, RSGOlea. (BRAZIL). [email protected]

5. EXPERIMENTAL MODEL OF HYPOTHALAMIC-PITUITARY-ADRENAL AXIS ACTIVATION-INDUCED IMMUNOSUPPRESSION IN BALB/C MICE. JM Viveros, AM Puebla, L Sandoval, MMVillaseñor. (MEXICO). [email protected]

6. EFFECT OF Ginkgo biloba EXTRACT, EGB 761 ON THE CELLULAR IMMUNE RESPONSE IN ANHYPOTHALAMIC-PITUITARY-ADRENAL AXIS ACTIVATION MODEL. MM Villaseñor, AMPuebla. (MEXICO). [email protected]

7. IMMUNOMODULATOR AND NEUROPROTECTOR ROLES OF FKBP51 AND FKBP52IMMUNOPHILINS IN UNIPOLAR AND BIPOLAR DEPRESSION. L. Pavón-Romero, G. Sandoval-López, I. Estrada-García, M. Pérez-Tapia, L. Gómez-Caudillo, J. Moreno, I. Arango, D. Gutiérrez,U. Ávila-Ordóñez, A. Hernández, C. Labastida, L. Álvarez, G. Heinze. (MEXICO)[email protected]

8. ROLE OF DENDRITIC CELLS IN ORAL TOLERANCE INDUCED DURING MICE LIFETIME. PUSimioni, DL Gabriel, LS Scuro, LGR Fernandes, WMSC Tamashiro. (BRAZIL)[email protected]

9. PHAGOCYTOSIS INMUNOMODULATION IN Balb-c 53 MICE FED WITH "MACA" Lepidiummeyenii AND "UÑA DE GATO" Uncaria tomentosa. A. Guerra, R. Gazis, J. Ramos (PERU)[email protected]

1 10. THE USE OF INTRAVENOUS IMMUNOGLOBULINS IN THERAPY OF INTRACTABLE EPILEPSY. E.Rojas, A. Cádiz, N. Sardiñas. (CUBA). [email protected]

1 12. OVERVIEW OF THE BIOCHEMISTRY AND SAFETY OF AN INTACT INTRAVENOUSIMMUNOGLOBULIN, pH 4.5. A. Cádiz, M.E. Castellano, A. Moya, J. Hernández, A. Rodríguez, E. Sosa, L.Joo. (CUBA). [email protected]

1 14. IMMUNOMODULATING ACTIVITIES OF PLEUROTUS OSTREATUS DERIVED PREPARATIONS.H.J. Morris, J. Marcos, G. Llauradó, N. García, R.C. Bermúdez, Y. Lebeque. (CUBA)[email protected]

1 15. HEPATIC HEMATOPOYESIS IN THE MICE WITH MYELOSUPPRESSION WITHCYCLOPHOSPHAMIDE AND TREATED WITH ALOE BARBADENSIS MILLER. José de La PazNaranjo, Maria del Carmén Sotolongo Baro, Maria E. Perdomo Paiba, Odalys Matos Reyes.(CUBA). [email protected]

1 16. A METHODOLOGIC VARIANT FOR THE REQUEST OF COMBINED VACCINE REGISTRY.Adriana Maria Perera, Néstor Expósito, Isabel Apezteguía, Caridad Torres, Xenia Muñoz, NubiaGonzález, Maxlenin Peña, Rafael Sánchez, Eduardo Martínez (CUBA)[email protected]

117. ESTABLISHMENT OF THE SYSTEM OF DOCUMENTATION OF A PRODUCT IN RESEARCH AND

DEVELOPMENT STAGE. Nubia N. González, Isabel Apezteguía, Maxlenin Peña, Dinorah Torres,Yaí Cruz, Llamil Ruiz, Matilde López, Natacha Pérez , Rolando Páez , Eduardo Martínez (CUBA)[email protected]

1 18. LIQUID PASTEURIZATION OF AN IMMUNOGLOBULIN PREPARATION WITHOUT STABILIZER.A. Cádiz, M. E. Castellano, A. Moya, A. Rodríguez, J. Hernández, L. Joo. A. Puig. (CUBA)[email protected]

1 19. PHAGOCYTIC FUNCTION OF POLYMORPHONUCLEAR NEUTROPHIL (PMN) LEUKOCYTES: ACOMPARISON BETWEEN FRESH AND 24 HOURS-OLD CELLS. I Torres, LO del Valle, V Marsán, M Sánchez, B Socarrás, M Ponce, RA Rivero, C Macías. (CUBA). [email protected]

220. STUDENT-SCIENTIFIC WORK IN IMMUNOLOGY TEACHING TO STUDENTS IN BIOCHEMISTRY.MC Pico, ME Alonso, J Díaz-Brito. (CUBA). [email protected]

221. IMMUNOLOGY TEACHING TO STUDENTS IN BIOLOGY, BIOCHEMISTRY AND MICROBIOLOGY.ME Alonso, MC Pico, A Otero, I Casadelvalle, L Calvo, G León, E Salas, J Díaz-Brito. (CUBA)[email protected]

2 22. CELLULAR IMMUNITY IN PATIENTS WITH CHRONIC GINGIVITIS EARLY AND LATEPERIODONTITIS. V. Hernandez, M. Chinea. (CUBA). [email protected]

2 23. IN VITRO EFFECT OF ATEROMIXOL ON LYMPHOBLASTIC TRANSFORMATION AND ONACTIVE ROSETTES FORMING CELLS. C. Insua, L. del Valle, C. Macias. (CUBA)[email protected]

2 24. IN VITRO EFFECT OF ACCUTE EXPOSURE TO LEAD ON HUMAN PERIPHERAL BLOODMONONUCLEAR CELLS. Miguel Angel Hernández -Urzúa, Galina Zaitseva -Petrovna, CeliaGuerrero Velazquez, Iris Estrada García, Mary Fafutis -Morris (MEXICO)[email protected]

225. ANTICOMPLEMENTARY ACTIVITY IN INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS. AAArce et al. (Cuba) [email protected]

IMMUNOLOGY AND REPRODUCTION

1. MOLECULAR MECHANISMS INVOLVED IN THE IN VITRO MODULATION OF HUMORALIMMUNE RESPONSES BY ESTROGEN AND PROGESTERONE. I Alvarez, L Berod, A Canellada,RA Margni. (ARGENTINA). [email protected].

2. DENDRITIC CELLS (DCs) MODULATE THE ASYMMETRIC ANTIBODIES PRODUCTION IN THECBA/J x DBA/2J MURINE ABORTION MODEL. S Blois, S Olmos, AC Zenclussen, T Gentile, PCArck, RA Margni (ARGENTINA-GERMANY/ARGENTINA-ALEMANIA). [email protected]

3. FUNCTIONAL AND PHENOTYPIC RESPONSE OF THE HUMAN NK CELLS IN NORMAL ANDPATHOLOGICAL PREGNANCY. J Puente, K Hidalgo, D Miranda, C Sepúlveda. (CHILE)[email protected]

AUTOIMMUNITY AND AUTOIMMUNE DISEASES

1. INTRAVENOUS IMMUNOGLOBULIN THERAPY IN STEVENS-JOHNSON SYNDROME. I. Navia, B.Conde, F. Castellano, A. Cádiz. (CUBA). [email protected]

2. -308 TUMOR NECROSIS FACTOR-ALPHA PROMOTER POLYMORPHISM IN PATIENTS WITHRHEUMATOID ARTHRITIS AND OSTEOARTHRITIS IN THE WEST OF MEXICO: PRELIMINARYRESULTS. E Oregón-Romero, JF Muñoz-Valle, S Ruiz-Quezada, BT Martín-Márquez, G Martínez-Bonilla, G Bernard-Medina, A Daneri-Navarro, M Vázquez-del Mercado. (MEXICO)[email protected]

3. THE -308 POLYMORPHISM IN THE PROMOTER REGION OF TUMOR NECROSIS FACTOR GENEAND EX VIVO LIPOPOLYSACCHARIDE-INDUCED TNF EXPRESSION IN PATIENTS WITHAGGRESSIVE PERIODONTITIS AND/OR TYPE 1 DIABETES MELLITUS. F González, C Pérez , AAguirre, V Pavez, V Araya, I Schiattino, J Cuenca, A Cruzat, JC Aguillón. (CHILE). [email protected]

4. RECOGNITION OF THE 117-125 PEPTIDE OF THE HSP60 FROM Klebsiella pneumoniae BY CD8T CELLS FROM ANKYLOSING SPONDYLITIS PATIENTS. F Zambrano-Zaragoza, D González-Juárez, R Burgos-Vargas, L Domínguez-López; M Cancino-Díaz, L Jiménez-Zamudio, E García-Latorre. (MEXICO) [email protected]; [email protected]

5. PAI-1 PROMOTER POLYMORPHISM IN PATIENTS WITH RHEUMATOID ARTHRITIS:PRELIMINARY RESULTS. S Ruiz-Quezada, JF Muñoz-Valle, BT Martín-Márquez, G Martínez-Bonilla, E Oregón-Romero, G Bernard-Medina, A Daneri-Navarro, M Cardenas-Meza, R Ascencio-Mendoza, M Vázquez-del Mercado. (MEXICO) [email protected]

6. THE ROLE OF CD4+CD25+ T LYMPHOCYTES ON INDUCTION OF ORAL TOLERANCE TOMYELIN BASIC PROTEIN. LMB Santos, A S Farias, JC Moraes, DEM Hallal, EC Oliveira, FGPereira, I Lorant- Metze. (BRAZIL/BRASIL). leonilda @unicamp.br

7. UNBIASED IDENTIFICATION OF ANTIGEN SPECIFICITIES OF CEREBROSPINAL FLUID-INFILTRATING T CELLS IN MULTIPLE SCLEROSIS. M Sospedra, Y Zhao, G Blevins, C Mora, RSimon, C Pinilla, R Martin. (SPAIN-USA/ESPAÑA-EEUU). [email protected]

8. CROSS REACTIVITY BETWEEN NON-CONSTITUTIVE EPIDERMAL ANTIGENS ANDSTREPTOCOCCAL ANTIGENS IN PSORIASIS. R Pérez-Lorenzo, D Sánchez-Sosa, M Chan-Avilés, G Abasolo-Flores, E López-Pacheco, G Bricaire-Bricaire. (MEXICO)[email protected]

9. THE ROLE OF HEAT SHOCK PROTEINS IN THE PATHOMECHANISM OF DIABETES MELLITUS.V Kecskemeti, A Szebeni, Z Prohaszka, K Tekes, Gy Fust. (HUNGARY/HUNGRIA)[email protected]

1 10. SELECTIVE DEPLETION OF Vb2+CD8+ T CELLS IN PERIPHERAL BLOOD FROM RHEUMATICHEART DISEASE PATIENTS. F Carrión, M Fernandez, LE Coelho Andrade, M Odete-Hilário, FFigueroa. (CHILE-BRAZIL/CHILE-BRASIL). [email protected]

1 11. DIABETOGENIC EFFECT OF CORN, RICE, BABASSU AND CASSAVA FLOUR. CJ Carvalho-Filho, EBS Barroqueiro, MVV Lima, NN Guedelha, FRF Nascimento, RNM Guerra.(BRAZIL/BRASIL). [email protected]

1 12. ANERGY AND APOPTOSIS OF ENCEPHALITOGENIC T LYMPHOCYTES IN EXPERIMENTALAUTOIMMUNE ENCEPHALOMYELITIS. AS Farias, DEM Hallal, BM Díaz-Bardales, SR Mirandola,LMB Santos. (BRAZIL/BRASIL). [email protected]

1

13. IL-1 beta, IFN gamma, IL-10 EXPRESSION IN PLACENTAL TISSUES OF PATIENTS WITHRHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS. G Martínez-Bonilla, JFMuñoz-Valle, G Orozco-Barocio, G Bernard-Medina, AM Gutiérrez-Chavarin, A Daneri-Navarro, VDelgado-Rizo, J Armendáriz-Borunda, M Vázquez-Del Mercado. (MEXICO)[email protected]

1

14. EXPRESSION OF IL-2, TNF alpha, IFN gamma, IL-4 AND IL-10, METALLOPROTEASE-9 ANDHORMONAL STATUS IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUSPREGNANT PATIENTS. JF Muñoz-Valle, M Vázquez-Del Mercado M, T García-Iglesias, GOrozco-Barocio, G Bernard-Medina, G Martínez-Bonilla, BE Bastidas-Ramírez, A Daneri-Navarro,M Bueno-Topete, CR Best-Aguilera, RE Navarro-Hernández, V Delgado-Rizo, J Armendáriz-Borunda. (MEXICO). [email protected]

1 15. ASSOCIATION OF MICA POLYMORPHISM WIHT TYPE I DIABETES RISK IN MEXICANFAMILIES. JF Mendoza Rincón, O Partida Rodríguez, I Soto Cruz, A García del Valle, B WeissSteider.(MÉXICO). [email protected]

1 16. AUTOANTIBODY DETECTION IN CHILDHOOD AUTISM. A PRELIMINARY REPORT. N Montiel,M Zavala. (VENEZUELA). [email protected], [email protected]

1 17. EXPRESSION OF IL4, IFN-GAMMA AND CD69 IN T LYMPHOCYTES OF PATIENTS WITHSPONDYLOARTHROPATHIES. I Girón-Pérez, Y Ortega-Ortega, R Burgos-Vargas, E García-Latorre, L Domínguez-López. (MEXICO). [email protected]

1 18. IL-13 RECEPTOR IN PSORIATIC KERATINOCYTES: OVER-EXPRESSION OF THE mRNA ANDUNDER-EXPRESSION OF THE PROTEIN. J Cancino-Díaz, E Reyes-Maldonado, L Jiménez-Zamudio, E García-Latorre, G León-Dorantes, F Blancas-González, M Cancino-Díaz. (MEXICO)Email: [email protected]

1 19. LYMPHOCYTE ACTIVATION FROM PSORIATIC PATIENTS BY RECOMBINANT HEAT SHOCKPROTEINS OF Streptococcus pyogenes. A. Pablo-Velázquez, M. Sánchez-Becerra, L.Domínguez-López, E. García-Latorre, L. Jiménez-Zamudio, G. León-Dorantes, M. Cancino-Díaz.(MEXICO). [email protected]

2 20. PREVALENCE AND ISOTYPE DISTRIBUTION OF ANTIPHOSPHOLIPID ANTIBODIES INUNSELECTED CHILEAN PATIENTS WITH VENOUS AND ARTERIAL THROMBOSIS. Iván Palomo,Jaime Pereira, Marcelo Alarcón, Marcela Vásquez, Carmen Pinochet, María T. Vélez, JorgeSandoval, Gloria Icaza, Silvia Pierangeli. (CHILE-USA / CHILE-EEUU). [email protected]

2 21. MANAGEMENT OF IMMUNE DISFUNCTIONS IN RESPIRATORY INFECTIONS IN PEDIATRICSPATIENTS. C.M. Santos Lagresa, M.N. Santos Lagresa, J. Galvez Varcarzel, M. Paredes, J.Corzo. (CUBA).

2 22. HLA-B27 AND ANQUILOSYNG SPONDILITYS ASSOCIATION IN CUBAN POPULATION. AdrianaArtiles, Flora Calzadilla, Lizette Bonet, Raul Ferreira, Aracelys Chico, Elena Kokuina. (CUBA)[email protected]

2 23. AUTOIMMUNE FEATURES IN SUBJECTS WITH SEVERE CORONARY ATHEROSCLEROSIS. Florde la C. Heres, Elena Kokuina, Josanne Soto, M. Beatriz Cabalé, Omar González , RobertoLlerena, Lorenzo Llerena. (CUBA). [email protected]

2 24. BEHAVIOUR OF THE CONCENTRATION OF IGG IN THE CEREBROSPINAL FLUID (CSF) INPATIENTS WITH SUSPECT OF DESMIELINIZANTES DISEASES OF THE CENTRAL NERVOUSSYSTEM (CNS). I Marten Powell, O. Gámez Rodriquez, E. Lay Georfe (CUBA)[email protected]

2 25. ANTIPHOSPHOLIPID SYNDROME: INFLUENCE OF SERUM COFACTORS IN THE REACTIVITYOF ANTICARDIOLIPIN ANTIBODIES. L. Muñoz, A. Griego, D. Mendoza. (CUBA).

2 26. FUNCTIONAL SUBSETS OF T CELLS IN THREE AUTOIMMUNE DISEASES. Góngora L, CoronaZ, Jorge C, Lahera R.(CUBA). [email protected]

2 27. DEVELOPMENT OF AN ATHEROSCLEROSIS MODEL INDUCED BY ACTIVE WAY OF IMMUNECOMPLEX FORMATION IN BALB/CBJ MICE. Lien López Matilla, Liudmila López Matilla, AdonisMontenegro Perdomo, Antonio González Griego, Leysis Mcloock, Aluet Borrego Alvarez, VictorManuel Sosa, José A. Castillo, Leonel Falcón Vilaut. (CUBA). [email protected]

2

28. DEVELOPMENT OF AN ATHEROSCLEROSIS MODEL INDUCED BY PASSIVE WAY OF IMMUNECOMPLEX FORMATION IN BALB/CBJ HEPATITIS B SURFACE ANTIGEN TRANSGENIC MICE.Liudmila López Matilla, Lien López Matilla, Adonis Montenegro Perdomo, Antonio GonzálezGriego, Victor Manuel Sosa, Leysis Mcloock, José A. Castillo, Leonel Falcón Vilaut. (CUBA)[email protected]

2 29. HANDLING OF DISIMMUNITARY STATES IN RELATION WITH OCULAR DISEASE. M.N. SantosLagresa, D. Vilches Lescaille, C.M. Santos Lagresa, T. Serrano. (CUBA).

3 30. CSF POLYSPECIFIC ANTIBODY RESPONSE IN MULTIPLE SCLEROSIS. MA Robinson-Agramonte, H Reiber, AJ Dorta-Contreras. (CUBA-GERMANY / CUBA-ALEMANIA)[email protected]

331. ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES IN PATIENTS WITH RHEUMATOID ARTHRITIS.M.V.Hernandez, A.M.Torres, I.M.Hernandez. (CUBA).

3 32. TOTAL ANTINUCLEAR AND NEURONAL ANTINUCLEAR ANTIBODIES IN PATIENTS WITHNEUROLOGIC DISEASES. PRELIMINARY STUDY. Odalis Asín Milán, Loida Torrez, Mabel MuñizRamos, Orestes Ponce of León, Roberto Alegre Mendez. (CUBA). [email protected]

3 33. EVALUATION OF THE TOXICITY OF THE HUMANIZED MONOCLONAL ANTIBODY T1HT INPATIENTS WITH RHEUMATOID ARTHRITIS. X Hernández, GA King, J Ducongé, L Roque.(CUBA). [email protected]

3 34. LABORATORY AND CLINICS CHARACTERISTIC IN HASHIMOTO'S THYROIDITIS. Y.R.Espinosa, R. Garcia, M.Savigne. (CUBA).

335. PREDICTIVE VALUE OF THE ANTINUCLEAR ANTIBODY SCREENING TEST FOR THE PRESENCE

OF AUTOANTIBODIES TO EXTRACTABLE NUCLEAR ANTIGENS AND TO dsDNA. ElenaKokuina, Isabel Matamoros, Ingrid García, Aracelys Chico, Miguel Estevez. (CUBA)[email protected]

3 36. AUTOIMMUNE HEMOLITIC ANEMIA (AHA). TREATMENT WITH INTACGLOBÍN.PRESENTATION OF A CASE. B. Rodriguez, A. Noda, A. Vidal (CUBA). [email protected]

337. RED CELL ALLOANTIBODIES IN CHILDREN WITH SICKLE CELL DISEASE. L Cortina, R López, ABencomo, T. García. (CUBA). [email protected]

3 38. COMPARISON OF THE INTACGLOBIN WITH THE PREDNISONE IN THE TREATMENT OF THETROMBOCITOPENIC PURPURE IMMUNOLOGIC (TPI). A. Noda, A. Vidal, B. Rodríguez (Cuba).E-mail [email protected]

3 39. INTACGLOBIN. THERAPEUTIC ALTERNATIVE IN THE DISSEMINATED LUPUSERYTHEMATOSUS. R. Alvarez, O. Sosa, M. Victoria. (Cuba)

4 40. PARTICIPATION OF PROLACTIN IN THE LYMPHOCYTES ACTIVATION FROM SYSTEMICLUPUS ERITHEMATOSUS PATIENTS. Legorreta-Haquet M.V. et al. (CUBA)[email protected]

INSTRUCCIONES PARA LA PRESENTACIÓN DE MANUSCRITOS A VACCIMONITORVacciMonitor es una publicación seriada irregular, dedicada a los temas de las vacunas: prevención de enfermedades, biología molecular,antígenos sintéticos, nuevos inmunógenos, adyuvantes, modelos animales, inmunidad, aplicaciones de desarrollo, pruebas clínicas, pruebas decampo, producción, epidemiología, eficacia, calidad y aspectos regulatorios, etcétera.

1. Se admiten manuscritos en español e inglés. Los artículos una vez queestén bajo consideración de Ediciones Finlay no podrán ser enviados aotras revistas, y después de aprobados para su publicación, ésta sereserva todos los derechos de reproducción.

2. Se aceptarán preferiblemente artículos originales, trabajos cortos en formade cartas al editor y excepcionalmente trabajos de revisión, los cuales seharán en la mayoría de los casos por invitación del Comité Editorial.

3. Los trabajos se presentarán en disquetes (preferiblemente en Word) yadjunto un impreso como mínimo de la versión manuscrita.

4. Las tablas, gráficos y figuras, con sus leyendas y títulos, deberán estarinsertados en Word y poseer cierto grado de profesionalidad. Se admitenfotos en B/N y color.

5. En general el texto no debe exceder de 15 páginas, incluyendo tablas,gráficos y fotos, con un formato de 81/2 x 11, un interlineado de 1,5 ó 2espacios, un puntaje tipográfico de 12, márgenes de 2,5 cm y el tipo depárrafo americano (sin sangría).

6. El Comité Editorial de VacciMonitor aceptará o rechazará los originales enfunción de las recomendaciones de los árbitros, su calidad científica y suidoneidad para la revista. Estos revisarán los trabajos y harán losseñalamientos de contenido que estimen convenientes, los cuales serándevueltos a sus autores para sus consideraciones y correcciones.Igualmente, en los manuscritos aceptados se realizarán las modificacioneseditoriales que se estimen necesarias, las cuales serán consultadas consus autores, siempre que sea factible. El autor devolverá el trabajo yacorregido en un plazo no mayor de dos meses; de no ser así el trabajo seráautomáticamente cancelado.

7. La autoría y coautoría será confirmada por escrito y firmada por cadamiembro del colectivo.

8. El título se escribirá con mayúsculas y minúsculas y contendrá el menornúmero posible de palabras.

9. El nombre de los autores y su primer apellido se escribirán completos. 10. Las reglas para citar la filiación son sencillas: poner la institución o centro,con su dirección, incluyendo el país. Se citarán en el mismo orden de losautores, utilizando para esto los superíndices (1; 2; 3; etcétera).

11. El resumen deberá aparecer en español e inglés y contener los elementosprincipales del trabajo en forma resumida (unas 250 palabras comomáximo).

12. Debajo de cada resumen se incluirán las palabras claves (un máximo deseis).

13. En el texto del artículo las referencias se numerarán consecutivamente, con

números arábigos entre paréntesis, sin superíndices, de la manera

siguiente: "Se ha observado (3, 4) que..." O bien: "Varios autores (1-5) han

señalado...". En ese mismo orden se agruparán al final del trabajo. Emplee

el estilo de los ejemplos que aparecen más adelante, los cuales están

basados en las Normas Vancouver, que a su vez es el formato que

utilizan en la Biblioteca Nacional de Medicina de los Estados Unidos en el

Index Medicus.

14. Absténgase de utilizar los resúmenes como referencias, tampoco lo haga

con las Observaciones inéditas y las Comunicaciones personales. En

cambio, se puede insertar en el texto (entre paréntesis) las referencias a

comunicaciones escritas, no verbales. Asimismo, incluya en las referencias

los artículos aceptados, aunque todavía no estén publicados; en este caso

indique el título de la revista y agregue "En prensa". La información sobre

manuscritos presentados a una revista, pero que aún no han sido

aceptados, cítela en el texto como Observaciones inéditas (entre

paréntesis).

15. Los autores verificarán las referencias cotejándolas contra los documentos

originales.

A continuación se presentan algunos ejemplos de formas correctas de

referencias.

Artículo ordinario:Inclúyase el nombre de todos los autores cuando sean menos de seis; si sonmás de siete, anótese la continuación et al o y otros; título del artículo; nombrecompleto de la revista (en cursiva); año; volumen; número del ejemplar (entreparéntesis); y páginas inicial y final. Toda la información se presentará en ellenguaje original del trabajo citado.

Guimaraes MC, Castilho EA, Celeste BJ, Nakahara OS, Amato Netto V.Almacenamiento a largo plazo de IgG e IgM en papel filtro para su uso enencuestas seroepidemiológicas de enfermedades parasitarias. Boletín de laOficina Sanitaria Panamericana. 1986; 100(1):129-144.

Libros y otras monografías:Se incluirán los apellidos e iniciales de todos los autores (o editores,

compiladores, etc.), o el nombre completo de una entidad colectiva; título (en

cursiva); número de la edición; lugar de publicación, entidad editorial y año.

Cuando proceda se agregarán los números del volumen y páginas consultadas,

serie a que pertenece y número que le corresponde en la serie.Colson JH, Armour WJ. Vacunas en el siglo XX. Barcelona: Ediciones Doyma;1990.

Capítulo de un libro:Soler C, Marchik EC. Pruebas de laboratorio para detectar infección por VIH. En:Ruiz GM, López H. SIDA, Ciencia y Sociedad. México: Fondo de CulturaEconómica; 1989:103-117.

Autor corporativo:España, Ministerio de Sanidad y Consumo. Alcohol y juventud. Madrid: Ministerio

de Sanidad y Consumo; 1991.

Actas publicadas de congresos, simposios, conferencias:Organización Panamericana de la Salud. Informes finales: 104ª y 105ªReuniones del Comité Ejecutivo de la OPS; XXIII Conferencia SanitariaPanamericana; XLII Reunión, Comité Regional de la OMS para las Américas.Washington DC, OPS, 1990. (Documento oficial 238).

Artículo presentado a una conferencia:Harley NH. Comparing radon daughter dosimetric and risk models. In: GammageRB, Kaye SV, eds. Indoor air and human health: proceedings of the Seventh LifeSciences Symposium, Knoxville, Tennessee, October 29-31, 1984. Chelsea,Michigan: Lewis; 1985:69-78.

Tesis doctoral:Youssef NM. School adjustment of children with congenital heart disease[dissertation]. Pittsburgh (PA): Univ of Pittsburgh; 1988.

Patente:Harred JF, Knight AR, Mcllntyre JS, inventors. Dow Chemical Company,assignee. Expoxidation process. US patent 3,654,317. 1972 Apr 4.

Contenido - InfomedOct.- Dic. del 2002 Año 11 No. 4 COMITÉ EDITORIAL Presidenta Concepción Campa...

Documents

Transcript of Contenido - InfomedOct.- Dic. del 2002 Año 11 No. 4 COMITÉ EDITORIAL Presidenta Concepción Campa...